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Abstract   
Focal adhesion complexes are mechanosensitive adhesion complexes that regulate key 
cellular processes such as cell migration and cell survival. These complexes connect 
the extracellular matrix (ECM) to the Actin network through a matrix-Integrin-Talin-
Vinculin-Actin complex. Vinculin is a linker protein that through its N-terminal head 
domain (VD1) binds to cryptic vinculin binding sites (VBS) in talin, while its tail domain 
binds to actin linking the actin network to the ECM. This study investigates key 
interactions between vinculin and VBS containing proteins. Proteins such as the 
chlamydial virulence factor TarP which hijacks vinculin to aid in bacterial internalisation, 
the Talin helix 50 VBS which seems unique in its ability to accommodate VD1 mutations 
that disrupt binding and lastly α-Catulin a vinculin homologue which could share 
interactions with any known vinculin binding proteins.  
We identified that the C.caviae Tarp VBS3 showed increased affinity for VD1 compared 
to the VBS1 and Pulldown assays showed that TarP may bind VD1 in a 1:3 ratio. We 
propose that TarP binding VD1 in a 1:3 ratio alongside the differences in affinity 
between its VBS indicate the possibility of infection stage specificity between VBSs.  
Talin H50 appears to accommodate VD1 mutants due to of lack polar/ionic bonds, 
alongside smaller side chained amino acids in the interface when compared to other 
VBS.  
Lastly, α-catulin shows conserved secondary structure with vinculin, as well as a 
potential interaction between α-catulin and the adhesion protein Paxillin. Indicating that 
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1.1 Cell-matrix Focal adhesion complexes 
The diversity in extracellular matrix (ECM) components in terms of type, topographical 
arrangement, ligand binding sites as well as physical differences when under varying 
degrees of forces are something that are acutely critical in cell development. This is 
seen when ablation of integrin subunits is embryonically lethal (Fässler et al., 1996). 
The way the cell communicates with the ECM is through bi-directional adhesion 
complexes, which utilise large cytoskeletal protein complexes to link ECM components 
to the interior of the cell. ECM components for example the fibrous protein Fibronectin 
are bound the extracellular portion of Integrins. Integrin proteins create the 
transmembrane link between the ECM and cytoskeletal proteins in the cell interior, in 
particular the mechanosensitive proteins Talin, Vinculin and the structural protein Actin 
which forms large fibrous networks involved in cell motility, cell-cell contact, cell cycle 
regulation and cell death (figure 1). This linkage of ECM-integrin-talin-vinculin-actin is 
the basic core of a focal complex, but as many as 232 proteins are found in be involved 
in the ‘adhesome’ (Winograd-Katz et al., 2014). As a cell migrates the cell membrane at 
the ‘front’ of the cell extends flat protrusions called Lamellipodium, which are highly 
enriched with branched actin networks (Jacquemet et al., 2015). Upon contacting the 
ECM, the cell forms nascent adhesions (NAs) which contain only a few hundred 
adhesion proteins, and which are only ~100 nm. NAs are transient (Changede et al., 




Larger more stable complexes can form when motor proteins such as Myosin IIa 
alongside actin binding proteins such as α-actinin bind to actin filaments to generate 
tension on these complexes (Choi et al., 2008). This generation of tension by myosin IIa 
as well as the ECM itself allows internal cytoskeletal proteins such as talin and vinculin 
(Ciobanasu et al., 2014; Pasapera et al., 2010) to act alongside numerous other 
cytoskeletal and signalling proteins to adjust cellular processes such as actin network 
growth and the eventual growth of NAs into a mature focal adhesion complexes (FACs).  
Figure 1-(left) Cellular interaction with the extracellular matrix through actin rich lamellipodia and 
filopodia extensions forms NA sites which eventually mature as forces increase and  adhesion 
proteins into are recruited forming focal adhesions. This allows cell migration and cellular sensing 
regulation. (Right) Close up of a mature focal adhesion showing the connection between the ECM, 
the α/β Integrin and focal adhesion proteins, Talin (FERM and Rod), Kindlin, focal adhesion kinase 
(FAK), Paxillin, Vinculin (VD1 vinculin head, VT vinculin tail), Kank proteins, cortical microtubule 
stabilising complex (CMSC) and actin. Redrawn from Jacquemet et al.,2015. 
Extracellular Matrix Extracellular Matrix 
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FACs can sense the ECM environment by specificity of ligand bound to the integrin 
receptor and by the mechanical forces applied through that connection. This Bi-
directional outside-in and inside-out signalling allows dynamic regulation of signals 
applied to either side of the FACs. Outside in signalling where the integrins extracellular 
ectodomains can bind extracellular ligands and these ligands can cause conformational 
changes in integrins which can also aid in integrin clustering. Inside out signalling 
requires that intracellular cytoskeletal proteins bind the integrin cytoplasmic tail to 
induce conformational changes which can lead to integrin activation and increased 
integrin ligand binding affinity (Shattil et al., 2010). A continuous dynamic equilibrium 
exists between the bi-directional signalling that while both seem to regulate individual 
steps both work in tandem to properly regulate adhesion assemblies.  
This dynamic regulation is possible because of the numerous adaptor/signalling 
proteins that can interact with the core adhesion proteins listed above. One of many 
important Signalling proteins is focal adhesion kinase (FAK) which is a non-receptor 
tyrosine kinase binds early on in focal adhesion sites and through autophosphorylation it 
can bind key structural proteins such as talin and Paxillin, notably paxillin a structural 
and signalling protein is required for FAK localisation at FA (Hu et al., 2014). Equally if 
not more importantly however FAK can bind and regulate though phosphorylation such 
regulating signalling molecules such as SRC kinase family proteins which can modulate 
numerous pathways from actin regulation through RAC and RHO GTPases, Myosin 
modulation and cell survival gene regulation through ERK kinase signalling (Burridge 
and Wennerberg, 2004).This mechanical/chemical type of regulation is decisive in stem 
cells as the interaction transduced from the ECM can have a direct on the outcome of 
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the cell in terms of morphogenic outcome, e.g. what lineage the stem cell will in 
differentiate into (Engler et al., 2006). 
1.2 Integrins 
Integrins are a heterodimeric protein that consist of non-covalently linked α and β 
subunits with large extracellular domains, each subunit having its transmembrane 
helices which then lead to individual C-terminal cytoplasmic tails. Mammals have 18α 
subunits and 8β units that form 24 different integrin types (Hynes, 2002) which all have 
varying tissue distribution such as αIIbβ3 integrins prominently found in platelets. The 
structure of integrins large inverted V-shaped extracellular domains is something that is 
key as it determines what activation state the integrin is in, three states have been 
observed bent-closed (inactive), extended-closed (active low ligand affinity) and 
extended-open (active high affinity) (Michael and Parsons, 2020). All integrin isoforms 
inhabit these three states, but some may be more or less likely to inhabit each state 
(figure 2). For example isoforms such as αvβ3 being more likely to inhabit the active 
state than αIIbβ3, this would depend on adaptor proteins present, ligand binding specific 
and isoform specific conformations (Litvinov et al., 2019). The two transmembrane 
helices are mediators of the varying activation conformations of integrins alongside the 
cytoplasmic tails discussed below. The ~20 Amino acid hydrophobic transmembrane 
helices interact with each other through two key interactions which keep the integrins in 
the more closed inactive conformations (Lau et al., 2009). An interaction in the outer 
leaflet of the plasma membrane allows the close packing of the two helices due to 
glycine packing motif GXXXG, which enables both α and β helices to pack together 
cooperating in keeping integrins in their inactive conformation (Russ and Engelman, 
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2000).This is known as the outer membrane clasp (OMC) (Lau et al., 2009) and 
mutations to more charged and bulky amino acids such as G to N in this region have 
resulted in increased integrin activation (Li et al., 2005). Another interaction aptly named 
the inner membrane clasp (IMC) contains a salt bridge which is positioned in the inner 
leaflet of the plasma membrane in proximity to the cytoplasm, which contains the highly 
conserved GFFKR in the α tail and HDR motif in β tails which also tend to have higher 
Figure 2-The different activation states of integrin molecules.1) Integrin in a low affinity 
conformation with no contact with ECM or intracellular proteins, 2a) an outside in signalling  
intermediate state with contact with the ECM, 2b) an different intermediate state showing inside out 
signalling with contact with intracellular proteins and 3) a high affinity state were the integrin 
molecule is in contact with both the ECM and intracellular proteins causing conformational changes 
between the α and β subunits. Redrawn from Mechanobio.info. 
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numbers of hydrophobic residues surrounding the motif than the α tails. In αIIbβ3 
integrins this salt bridge exists between αIIb R995 and β3 D723 and again mutations to 
oppositely charged residues increased integrin activation (Hughes et al., 1996; Luo et 
al., 2005, 2004). Both these interactions are relatively weak, and both are required to 
keep integrins in their closed inactive conformation.  
To activate integrins a combination of interactions occur between the large 
mechanosensitive protein talin N terminal FERM domain and the integrin β cytoplasmic 
tail, although many interacting proteins have roles in partially activating integrins 
discussed below .These interactions between talin FERM domain and β tails cause 
conformational changes in the extracellular ectodomains (Xiong et al., 2010) and 
transmembrane domains of integrins allowing the stabilising interactions mentioned 
above to be disrupted resulting in integrin activation (Anthis et al., 2009).  
1.3 Talin 
The link between integrins and the actin cytoskeleton is facilitated by a 270 kDa 
mechanosensitive cytoskeletal protein called talin (Burridge and Connell, 1983). Talin 
has a modular structure  made up of 18 singular domains which can be  broadly 
separated into two main larger domains (figure 3). The N-terminal of talin contains a 
FERM (4.1 protein, ezrin, radixin, moesin) domain (Chishti et al., 1998) which itself is 
made up of four separate domains, F0,F1,F2 and F3 (Pearson et al., 2000).This being 
an atypical arrangement of FERM domains because talin has a duplicated F1 domain 
named F0 which is shared only by Kindlin molecules and no other FERM domain 
containing proteins (Goult et al., 2010).  
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The N terminal FERM domain is connected to a large Rod domain by a short ~80 
residue disordered linker region which contains a calpain protease cleavage site which 
is essential in the attenuation of FACs (Franco et al., 2004). The large rod domain 
consists of 13 4 and 5 helix bundles aptly named R1-R13, followed  by a single C-
terminal helix dimerization domain (DD) allowing homodimerization (Gingras et al., 
2008; Goult et al., 2013a; Senetar et al., 2004). 
A Rap1-GTP–interacting adaptor molecule (RIAM) binds to the R2-R3 domain and 
recruits talin to the cell membrane allowing talin to interact with integrin cytoplasmic tails 
Figure 3-A)Talin the mechanosensitive adhesion protein containing the N-terminal FERM domain (F0-
F3), F3 being important in integrin activation proceeding is an 80-residue disordered linker region. 
Attached to the linker region is the 13 alpha helical bundle Rod domains (R1-R13) which 9 out the 13 
domains contain cryptic VBS (Red). At the C-terminus is a dimerization for forming homodimers 
between two Talin molecules. Redrawn from Khan and Goult, 2019. B) RIAM binds to the folded R3 
domain talin, once tension is applied across the talin rod the R3 domain unfolds displacing RIAM and 
allowing VD1 to bind. Redrawn from Goult et al., 2018. 
 
Figure 4-Talin in its autoinhibited conformation held in place through interactions between F3 and 





(Lee et al., 2009).Talin exists in an autoinhibited conformation were interactions 
between F3 and R9 domains keep talin locked in this conformation (Dedden et al., 
2019; Goult et al., 2013a, 2009; Khan and Goult, 2019) (figure 4). Freed by a 
combination of binding interactions between the membrane phospholipid 
phosphatidylinositol 4,5-bisphosphate (PIP2) binding to F1-F3 causing conformational 
changes that expose the IBS1 (Goksoy et al., 2008; Kelley et al., 2020; Song et al., 
2012) and RIAM R2-R3 binding (Han et al., 2006). 
1.3.1 Talin FERM domain 
The FERM domain binds several proteins through each of its four domains for example  
phosphatidylinositol 4-phosphate 5-kinase 1 (PIP1 γ90) (Di Paolo et al., 2002; Ling et 
al., 2002) a kinase that binds to F3 that facilitates the production the aforementioned 
PIP2, an actin binding site (ABS) across F2-F3 and the integral integrin binding site 
(IBS1) in F3.Talin binds to the integrin β cytoplasmic tail through interactions between 
the talin F3 domain and a membrane proximal NPXY in the β cytoplasmic tail 
(Calderwood et al., 1999). An additional NPXY site exists in the β cytoplasmic tail at a 
more C-terminal position to which another FERM domain containing protein named 
Kindlin binds and assists in integrin activation (Harburger et al., 2009). F3 binding 
causes a conformational change in the membrane proximal region of integrins, the 
previously mentioned IMC region. Conserved lysine residues in (Talin1 324/Talin2 327) 
disrupt the IMC salt bridge and cause the reorientation of the integrin transmembrane 
helices by 20°, disrupting the OMC glycine packing also (Anthis et al., 2009). Membrane 
orientation patches consisting of positively charged residues present in F2 and in a loop 
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region in F1 help orientate the talin FERM domain to maintain integrin/talin interactions 
(Kalli et al., 2010). 
1.3.2 Talin Rod 
Each talin rod domain contains binding sites for a variety of ligands such as the Kank 
proteins (Bouchet et al., 2016), vinculin and actin etc. Regulation of ligand binding is 
something that can depend on the structural conformation of each bundle, these can be 
altered by post translational modifications such as phosphorylation and methylation 
among others (Gough and Goult, 2018) but by far the most important is mechanical 
force. For any mechanical force to be applied through talin it must be tethered , and this 
initially achieved through talin-integrin binding and talin-actin binding. Talin has three 
ABS, (Hemmings et al., 1996) ABS1 in F2/F3, ABS2 extending across R4-R8 (Atherton 
et al., 2015) and ABS3 spanning R13-DD (Gingras et al., 2008). Actin binding to any of 
these sites alongside actomyosin pulling on the filaments themselves will generate 
tension across the talin molecule. Tension across the rod domain can unfold these rod 
helical bundles exposing cryptic binding sites. Each domain will unfold at specific levels 
of pN force owing to specific residue interactions present in each helical bundle, with 
increasing force up to 30 pN whereupon all domains are unfolded (Yao et al., 2016). 
This variety in force required to unfold each domain alongside their unique ligand 
interactions allows talin to act as a dynamic mechanosensitive signalling hub (Goult et 
al., 2018), transmitting external and internal forces into both structural signals through 
conformational changes within talin and chemical signals that recruit signalling 
molecules to relay changes in the FACs. One main group of binding sites that are 
hidden inside these domains and are exposed upon force are vinculin binding sites 
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(VBS) (Atherton et al., 2015; Gingras et al., 2005) to which there are 9 helical bundles in 
the talin rod that contain one or two of these cryptic VBS 
This change in ligand binding dependence on helical bundle conformations is 
exquisitely seen in the alternation between the RIAM and vinculin binding, Vinculin 
being a large structural actin/talin linker protein discussed in detail below. RIAM binds to 
R2-R3 but only when the R3 domain remains in its folded conformation, upon release of 
talin autoinhibition and binding to integrin and actin, tension is created across the rod 
domains and R3 becomes unfolded. Vinculin can now bind to the unfolded R3 domain 
which now has two VBS exposed, this mechanochemical switch of RIAM being 
exchanged for vinculin when force is applied is key for the maturation of focal 
complexes (Goult et al., 2013b; Yao et al., 2014a) (figure 3).The large variety of ligand 
binding to each rod domain is coupled to an additional dependence on each rods 
conformation, allowing talin to be the one of the most influential mechanosensitive 
regulatory proteins in the cell.  
The importance of talin and its dynamic regulation in cells is seen when talin is 
downregulated or ablated, disruption of talin has been shown to arrest mouse embryo 
development early on at the gastrulation stage (Monkley et al., 2000). Talin ablation can 
cause defects in skeletal muscle development  disrupting myotendinous junctions 
leading to progressive myopathies (Conti et al., 2009).Talin overexpression is 
associated with increased resistance to cell anoikis, increased metastasis and as such 
is linked to many cancers such as prostate (Zhang et al., 2015) and oral squamous cell 




1.4 Vinculin  
Vinculin is a 116 kDa (1066aa) mechanosensitive linker protein prominent in integrin 
based focal adhesions and cadherin-based cell-cell complexes. Vinculin is separated 
into anti-parallel α-helical bundles consisting of a large N-terminal head domain 
consisting of four subdomains VD1-VD4, this is followed by a disordered proline rich 
linker region which connects the head domain to the C terminal tail domain (VT) (figure 
5). This proline linker contains binding sites for vasodilator-stimulated phosphoprotein 
(VASP), Vinexin (Kioka et al., 1999), Ponsin (Mandai et al., 1999) and the Actin 
recruiting protein 2-3 complex (Arp2/3) (DeMali et al., 2002; Golji and Mofrad, 2013; 
Omachi et al., 2017). The vinculin D1 domain (VD1) can bind cytoskeletal proteins such 
as talin (Gilmore et al., 1992), α-actinin (McGregor et al., 1994), α-catenin (Watabe-
Uchida et al., 1998; Yao et al., 2014b), β-catenin (Hazan et al., 1997; Peng et al., 2010) 
and its own VT (Johnson and Craig, 1994). VD1 is also the target of bacterial invasive 
molecules such as Shigella flexneri IpaA invasin (Hamiaux et al., 2006) and Chlamydial 
translocated actin recruiting phosphoprotein (TarP) molecules (Clifton et al., 2004) 
which allow bacterial entry into cells. 
The VT region has binding sites for actin, paxillin (Turner et al., 1990; Wood et al., 
1994), PIP2 (Johnson et al., 1998) and the VD1 domain. The VT contains two ABSs 
(Hüttelmaier et al., 1997) that allow vinculin to link the actin cytoskeleton at its C-
terminus to the cytoskeletal proteins bound at its N-terminus such as talin. Vinculin can 
undergo VT-VT homo-dimerisation (Bakolitsa et al., 1999) being facilitated by both PIP2 
(Hüttelmaier et al., 1998) and actin (Johnson and Craig, 2000) which interacts with VT 













Vinculin Head VD1-VD4  
D               Proline 
linker VD1 VD2 VD4 VD3 VT 
aa: 1-252 253-485 493-717    719-835   896-1066 838-878 
Figure 5-(Top) Structure of full-length Vinculin in its autoinhibited head-tail state showing each of its 
five domains VD1 blue,VD2 green, VD3 yellow, VD4 pink and VT red. PDB 1ST6 Bakolitsa et al., 
2004. (Bottom) Domain boundaries VD1-5 of vinculin including proline linker region.  
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linking the two. Additionally, trimers can also be formed when PIP2 molecules in a dimer 
interacts with the α-3 helix of a vinculin monomer (Chinthalapudi et al., 2015). Vinculins 
linker role in these complexes is highly regulated and regulation is primarily attributed to 
Vinculins structural conformations. 
Vinculin is maintained in an autoinhibited state via hydrophobic and hydrogen bond 
interactions between the VD1 domain binding to the VT (Izard et al., 2004), alongside 
polar interactions between VD3 and VT (Bakolitsa et al., 2004) and both ionic and 
hydrogen bonding interactions between VD4 and the VT (Cohen et al., 2005). The VD1 
to VT interaction being the most important but the additionally interactions of both VD3 
and VD4 increase the affinity by almost a hundred-fold (figure 6). 
Autoinhibited vinculin is its cytoplasmic state until it is recruited into one of these 
adhesion complexes. To release vinculin from its autoinhibited state one hypothesis 
propose a combination of F-actin binding to the VT and talin VBS binding to VD1 must 
occur to disrupt these intramolecular interactions activating vinculin (Chen et al., 2006).  
Although another hypothesis proposes that the VBS in proteins such as talin or α-actinin 
binding to VD1 are sufficient to activate vinculin (Bois et al., 2006; Golji and Mofrad, 
2010). 
The VBSs present in proteins such as talin and α-actinin participate in the activation of 
vinculin by binding to VD1 through the insertion of a amphipathic helix into the core of 
N-terminal of VD1 (Izard et al., 2004) the N-terminal consisting of four α helices (1-4) 
and C-terminal (4-7) (figure 7). 
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Figure 6-(Top) Structure of vinculin VD1 and VT in an autoinhibited conformation.(Bottom) Hydrogen 
bonds as well as hydrophobic packing maintain the VD1-VT interaction, which are subsequently 
disrupted upon helical insertion of VBS such as those found in talin. VT α1-5 helices. PDB 1RKE Izard 








This insertion occurs between the α1 and α2 helices and converts this VD1 N-terminal 
region into a 5-helix bundle, with the hydrophobic faces of the helix interacting the 
hydrophobic residues present in the core of the N-terminal bundle (Tran Van Nhieu and 
Izard, 2007).This helical addition causes structural rearrangements in VD1 that facilitate 
the weakening of the VD1-VT interaction, favouring vinculin activation. 
Additionally, tension applied from the binding at the N and C termini are also important 
to maintain vinculin in its activated state as loss of tension across the molecule can lead 
to the rapid inactivation of FACs (Grashoff et al., 2010). Phosphorylation of key residues 
Y100, Y1065, S1033 and S1045 are also known to be important in regulating D1-VT 
interactions as these phosphorylations can alter charged residues orientations in D1, 
weakening head to tail interactions (Auernheimer and Goldmann, 2014; Golji et al., 
2012; Zhang et al., 2004). The combinatorial binding of talin and actin binding appear to 
be needed in releasing vinculin from this autoinhibited state and the phosphorylation 
Figure 7-The insertion of the VBS (orange) helix forces the helices α1 and α2 of the N-terminal helical 
bundle of VD1 (blue) apart and allows the VBS to insert itself into the hydrophobic core, thus 
converting the 4-helix bundle to five helix bundle. This interaction disrupts VD1-VT interactions and is 











Sites aid in maintaining it in the activated state. Autoinhibited vinculin is thought to be 
recruited to FACs by paxillin in a proposed hand off model, where increased myosin II 
activity increases paxillin binding to vinculin which then transports vinculin to FACs 
where it is ‘handed’ to talin (Pasapera et al., 2010). Once recruited to FACs 
autoinhibited vinculin replaces RIAM bound to talin R2-R3 to favour more stable 
adhesions and turnover and by the regulation of actin through its own ABS (Thievessen 
et al., 2013) and through interactions with actin regulatory proteins such as ARP2/3 
(Chorev et al., 2014). Vinculin acts as a force transduction protein which transmits force 
from the ECM to the actin cytoskeleton and vice versa, which when under high degrees 
of force ultimately leads to an increase in size and stability of FACs through integrin 
clustering and increased links to the actin cytoskeleton (Hernandez-Varas et al., 2015). 
This increase in FACs stability and size caused by an increase in force means that 
more talin is recruited, this increase in force means more talin VBS are available for 
vinculin to bind and be activated by talin/actin binding.  
FACs disassembly is required to allow the cell to form new adhesions and continue to 
migrate, a loss of force across FACs causes the loss of talin from the complex. Talin is 
cleaved through its calpain cleavage site found in the linker between the FERM and rod 
domains (Franco et al., 2004). This loss of talin alongside proposed PIP2 interactions 
disrupting actin-VT bonding result in loss of tension across vinculin, allowing vinculin to 
revert  back to its high affinity autoinhibited conformation (Chandrasekar et al., 2005; 





1.4.1 Exploring vinculin associated interactions in the cell 
Studies of vinculins many binding interactions with both structural and signalling 
proteins have shown how essential it is for cell migration and survival across many 
species. In some bacterial such as chlamydial bacteria host vinculin is considered 
essential for the continuation of a pathogenic cycle that sees vinculin hijacked and 
repurposed for bacterial invasion into a host cell. In Drosophila vinculin is considered 
non-essential in enabling embryos to grow into fully formed adults, however when 
vinculin is overexpressed it can result in lethality (Maartens et al., 2016). Lastly vinculin 
has two homologous proteins α-catenin which has a role in cell-cell adhesion complexes 
and α-catulin which is associated with the dystrophin associated protein complex 
(DAPC) which forms strong connections between the ECM and the cell interior in 
muscle tissues (Petrof et al., 1993). The least studied of these is α-catulin, its structural 
homology to vinculin could mean it shares some of the same essential binding 
interactions seen in vinculin. Here in this study we will investigate three separate 
aspects of vinculin cellular interactions. 
1.To investigate a Chlamydial virulence factor that can bind and hijack vinculin to aid in 
the internalisation of the chlamydial bacteria  
2.How vinculin mutants that can rescue Drosophila from hyperactive vinculin bind and 
interact with different talin VBS 





1.5 Chlamydial pathogenesis and the Vinculin recruiting virulence factor Tarp 
Project 1 will look at the importance of vinculin in several cellular processes including 
cell motility and adhesion has led bacterial pathogens to opportunistically recruit vinculin 
to alter cell cytoskeletal dynamics. One bacterial pathogen family being the Chlamydia 
family of bacteria, which are obligate intracellular bacteria that have been found to 
subvert host cytoskeletal proteins to aid in its pathogenesis (Abdelrahman and Belland, 
2005). 
Chlamydia bacteria are responsible for the majority of sexually transmitted infections 
across the globe (Howie et al., 2011) and are also one of the main causes of 
preventable blindness (Eko et al., 2008), this ability to infect mammalian cells so well is 
largely due to its unique pathogenesis cycle (Elwell et al., 2016). Extracellularly 
Chlamydia bacteria exist as infectious elementary bodies (EB) that when encountering a 
suitable host cell will attach initially through low affinity heparan sulfate proteoglycans 
(HSPGs) on the cells surfaces (Taraktchoglou et al., 2001), then high affinity cell 
receptor binding with such proteins as β1 integrin (Stallmann and Hegemann, 2016), 
mannose 6-phosphate receptor (Puolakkainen et al., 2005) and protein disulfide 
isomerase (PDI), all of which have been shown to be important in chlamydia bacterial 
entry into cells (Conant and Stephens, 2007). The binding of the EB with these host cell 
receptor causes actin remodelling inside the host cell to aid in the internalisation of the 
EB (Carabeo et al., 2002) and enable further EB membrane interactions that can alter 
MEK–ERK and phosphoinositide 3-kinase (PI3K) host cell survival pathways (Kim et al., 
2011; Subbarayal et al., 2015).The binding to host cell receptors is highly variable, 
differing chlamydial species and host cell tropism are seen to play their part in the large 
32 
 
variations in receptor bindings. Upon binding the EB injects premade virulence 
enhancing proteins into the host cell through a type three secretion system (T3SS) 
(Beeckman and Vanrompay, 2010; Slepenkin et al., 2003). These virulence factors can 
induce alterations in cellular signalling and cytoskeletal protein recruitment to aid in the 
internalisation of the EB. One such virulence factor is the TarP which has been shown 
to bind to both actin and vinculin and facilitates EB entry into the cell (Clifton et al., 
2004).  
Once the EB has been internalised in a membrane-enclosed compartment known as an 
inclusion, the EB inside the inclusion then undergoes differentiation into a non-infectious 
reticulate body (RB) (figure 8). Numerous proteins both on the surface of the inclusion 
and injected from the inclusion into the cytosol can allow the RB to survive in the host 
cells cytosol by scavenging nutrients and subverting cell apoptotic pathways . Examples 
being soluble N-ethylmaleimide–sensitive factor attachment protein (SNARE) proteins 
that associate with the inclusion membrane and scavenge nutrients from Golgi 
exocytotic vesicles (Lucas et al., 2015), and proteins such as cellular flice-inhibitory 
protein (cFLIP) that can interfere with caspase8 activation thereby controlling apoptosis 
(Böhme et al., 2010; Irmler et al., 1997) In later phases of infection the RB will replicate 
and then undergo secondary differentiation back to an Eb, at the same time expressing 
proteins such as the chlamydia protease-like activity factor (CPAF) (Snavely et al., 
2014) that aid in the lysis of the host cell so that the EB can be free to begin another 
round of infection on a neighbouring host cell. Alternatively, the infected cell may 
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methodically exocytose EBs without lysing the cell, which requires the remodelling of 
the actin network through N-WASP a RhoA GTPase and Myosin II which facilitates 
membrane pinching to release the EBs (Hybiske and Stephens, 2007). This alternative 
method allows the cell to maintain a continuous stream of infectious EB while limiting 
the hosts immune response, as there is no release of cellular debris that is detected in 
lysis of a cell by immune cells.  
A 
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RB 
Figure 8-The chlamydial pathogenesis cycle stages from EB internalisation aided by TarP though 
differentiation into an RB, before multiplying and differentiating back into a EB before the cell undergoes 




The intrinsically disordered TarP 90 kDa protein is key in the initial invasion of 
chlamydial EB largely due to its ability to bind and commandeer host vinculin (Thwaites 
et al., 2015) and actin (Jewett et al., 2006; Tolchard et al., 2018) and alter a host cells 
structural complexes to facilitate the internalisation of EBs. TarP is conserved across all 
the chlamydial family albeit with species specific differences. Some orthologues such as 
C.trachomatis contain an additional set of tyrosine repeats in their N-terminal domain 
which are missing in others (Clifton et al., 2005), these repeats can be phosphorylated 
and cause actin rearrangement and stimulate host survival pathways (Elwell et al., 
2016) . Also, the chlamydial family shows variation in the number of both ABSs and 
VBSs present in each orthologue, each having a range of 1-3 ABS and 1-3 VBS 
(Thwaites et al., 2015). The C.caviae TarP ortholog consists of a single leucine/aspartic 
acid (LD) motif, two Wiskott-Aldrich homology 2 (WH2) ABS alongside 3 VBS at the 
disordered C-terminal (1-3 C-terminal to N-terminal). C.caviae is differs from many of 
Figure 9-The C.caviae TarP virulence factor contains multiple binding domains primarily located at its 
C-terminus which aid in its remodelling of adhesion complexes for EB internalisation. C.caviae TarP 
contains one LD motif, two ABS and uniquely three VBS. Redrawn from Whitewood et al., 2018. 
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Chlamydial TarPs as it lacks an regulatory N-terminal phospho-domain that is found 
many TarPs (Clifton et al., 2005) as well as containing and three VBS which is unique 
among TarPs (Thwaites et al., 2015) (figure 9).   
TarP is injected into the host cell through the T3SS and binds vinculin and actin 
alongside host actin regulatory proteins such as the ARP2/3 complex (Jiwani et al., 
2012) as well as host signalling proteins to modulates cellular dynamics in favour of 
facilitating the internalisation of the EB. In C.caviae TarP’s actin recruitment was shown 
to be vinculin dependent (Thwaites et al., 2015) and it is proposed that the interactions 
Figure 10-A comparison between an integrin based FACs (left) and an adhesion complex formed though 
TarP hijacking vinculin and remodelling the actin cytoskeleton to aid in the internalisation of an EB (right). 
Vinculin plays a role in in the formation of both complexes, its ability to bind and regulate actin 
remodelling as well as being a linker protein make it key for the formation of actin networks. 
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between vinculin bound to the TarP VBS regulates this actin recruitment and assembly 
at the cell membrane.  
TarP interacts with vinculin through binding to VD1 via the same helix addition method 
as talin and disrupts the VD1-VT interactions, relieving it from its autoinhibited state. 
While isolated TarP and talin VBS both bind with similar affinities, TarP’s VBSs are 
present in a disordered region meaning they are constitutively able to bind vinculin 
whereas in talin an application of force is required to uncover the cryptic VBSs inside 
each talin rod helical bundles (Yao et al., 2014a). This results in TarP being able to 
outcompete talin (Whitewood et al., 2018) in binding to free vinculin and subsequently 
recruit vinculin to aid in EB internalisation. 
C.caviae’s 3 TarP VBSs all share conservation with the VBS found in talin as well as 
other vinculin binding bacterial virulence factors such as Rickettsia surface antigen sca4 
(Lee et al., 2013; Park et al., 2011a) and Shigella IpaA invasin (Hamiaux et al., 2006; 
Park et al., 2011b) which both bind vinculin and reorganise actin networks. While 
C.caviae TarP VBS1 VD1 binding data is known (Whitewood et al., 2018), less is known 
about the other two VBS and in this chapter we will attempt to characterise and 
compare them. 
This projects aim is to biochemically and biophysically characterise the interactions and 
structure of VD1 with TarP VBS2 and 3, so as to make direct comparisons with VBS1. 
Also, as C.caviae TarP is unique in having three VBS determining the stoichiometry of 
vinculin molecules able to bind at any one time may enable further insight into the 
importance of each VBS.  
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1.6 Vinculin lethality rescuing mutants  
Vinculins plays are large role in FACs and cadherin cell-cell complexes and regulating 
vinculin recruitment and activation that allows a cell to adapt to its dynamic environment 
(Leerberg and Yap, 2013). Vinculin’s importance in embryogenesis has been shown to 
vary between species with some species showing higher sensitivity to its ablation and/or 
up regulation. 
Vinculin’s effects on embryogenesis have been shown in vinculin gene knockouts in 
several animal models. C.elegan vinculin null worms die in the larval stage due to 
abnormal muscle dystrophy having gone through an elongated embryogenesis 
(Barstead and Waterston, 1991). Vinculin null mice also show large defects in 
development with cardiovascular and neural tube closure defects appearing as early 
day as E8 followed by death at day E10 (Xu et al., 1998; Zemljic-harpf et al., 2004). In 
contrast in zebrafish vinculin appears to be of less importance with both isoforms 
(zebrafish having two vinculin isoforms VA/VB) being able to be deleted with only mild 
pericardial edemas (excess fluid between the heart and the sack around the heart ,the 
pericardium), the zebrafish grew to adulthood without major issue (Han et al., 2017). In 
Drosophila melanogaster vinculin null mutants are able to progress through 
embryogenesis and were still viable with only very mild defects in adult musculature. 
While vinculin null Drosophila only had mild defects (Alatortsev et al., 1997), it was 
shown that a constitutively open (CO) hyperactive vinculin where the autoinhibitory 
head to tail interactions are disrupted caused lethality (Maartens et al., 2016). CO 
vinculin in Drosophila was found at FACs but also in cytoplasmic aggregates. These 
subcomplexes require talin to form and addition of a singular talin VBS helix disrupted 
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the aggregate formation indicating talin was associated with these complexes through 
vinculin-talin VBS interactions. These subcomplexes do not appear to the cause of 
lethality and it appears the VD1 region binding talin at FACs caused the lethality. It is 
likely that due to CO vinculin interfering with FA turnover through constant binding to 
talin VBS it might disrupt the cycles of talin VBS bundles unfolding and refolding which 
are needed for mechano-transduction force signals (Maartens et al., 2016). This could 
lead to an overstimulation of FACs assembly and lifetime resulting in improper 
maintenance of mechanical signal transduction.  
The interaction between talin’s VBSs and vinculin appeared to be key to lethality, and a 
set of mutations in VD1 were discovered through a genetic screen, where mutations to 
the CO vinculin gene were made to identify if any supressed lethality. Mutations to VD1 
in CO vinculin appeared to supress lethality and it was assumed that these mutations 
disrupted VD1 talin VBS binding. Three VD1 mutations A50I, P15L and W253X rescued 
Drosophila from lethality and the mutants showed reduced equilibrium dissociation 
constant (Kd) values when binding talin VBS (Data generated by Dr Karen Baker 
Postdoc in the Goult lab) confirming the assumption that the mutations disrupted VD1 
talin VBS binding.  
A talin VBS helix 50 (H50) showed only small reductions in Kd when binding the VD1 
mutants when compared to wildtype (WT) VD1,and were still able to effectively bind 
helix 50 and rescue the Drosophila from lethality as was seen in the other talin VBS 
tested. This could indicate a different binding model may be present between A50I, 
P15L and W253X and talin H50. 
39 
 
Using x-ray crystallography, the intention is to crystallise each of the three vinculin 







1.7 α-Catulin and the dystrophin associated protein complex 
Vinculin has been shown to be a highly regulated part of FACs as well as in cadherin 
complexes acting as a strengthening and mechanosensitive signalling/adaptor protein. 
A protein with high sequence and structural homology to both vinculin and α-catenin 
called α-catulin has been found to be involved in another cytoskeletal adhesion complex 
the DAPC. The DAPC is a complex important in force transmission in muscle cells, 
where α-catulin too appears to play an adaptor/signalling roles. 
1.7.1 DAPC 
The DAPC is another large protein complex that links the ECM to the actin/microtubule 
cytoskeleton and plays a large role in the transmission and resistance of force in muscle 
tissue particularly skeletal and cardiac. Regulating and transmitting force between the 
sarcolemma (membrane surrounding striated muscle) and the ECM (Petrof et al., 1993). 
Additionally, the DAPC is vital in the formation, maturation, and maintenance of 
neuromuscular junctions (NMJ) (Belhasan and Akaaboune, 2020; Repository et al., 
2002). 
The DAPC is made up of a core collection of proteins such as Dystrophin (Deconinck et 
al., 1997), a dystrophin homolog utrophin (Winder et al., 1995), Dystroglycans, 
Sarcoglycans, Sarcospan, Syntrophins, and Dystrobrevins (Gawor and Prószyński, 
2018). However, these proteins make up only the core structural complex, numerous 
adaptor/signalling proteins also decorate this complex. These include neuronal nitric 
oxide synthase (nNOS) which creates nitric oxide a neurotransmitter which regulates 
synaptic signalling and muscle contractions in NMJ, alongside regulating oxygen usage 
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in muscle sarcolemma as well as all neuromuscular tissues (Adams et al., 2008; Chang 
et al., 1996; Mungrue and Bredt, 2004). Other signalling proteins include the growth 
factor receptor-bound protein 2 (Grb2) (Yang et al., 1995a) which is involved in actin 
organisation as well as being involved in cellular signalling (Giubellino et al., 2008), and 
α-Catulin (Oh et al., 2012) which can all interact with the DAPC core proteins and aid in 
the regulation and transduction of physical and chemical signals.  
The importance of the DAPC’s role in muscle/NMJ maintenance and formation became 
evident when ablation of dystrophin or other core DAPC proteins can cause Duchenne 
muscular dystrophy (DMD) (Ervasti et al., 1990), a condition that causes muscle 
weakness and atrophy in skeletal and cardiac muscle (Isaac et al., 2013; Matsumura et 
al., 1992; Ohlendieck and Campbell, 1991). Mutations in several regulators of core 
proteins of the DAPC can lead to other myopathies such as Walker-Warburg syndrome 
(WWS) a muscular dystrophy which can cause abnormalities in the eye and brain. 
WWS can be caused through mutations in a glycosylation enzyme protein O-
mannosyltransferase 1 (POMT1) which causes hypoglycosylation of α-dystroglycan 
resulting in reduced ECM binding (Van Reeuwijk et al., 2005). 
The large and varied number of myopathies associated with mutations in the DAPC  is 
due to the many overlapping interactions between DAPC proteins. Whilst dystrophin 
acts as the main scaffold in the DAPC there are many other protein interactions within 
the DAPC that regulate and maintain the whole complex and as such causes the many 
types of myopathy.  
The key protein in the DAPC is the 427 kDa dystrophin protein, which acts as the main 
scaffolding/signalling hub in the DAPC much like talin in FACs. Dystrophin has a large 
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central 24 Spectrin like repeat domain (Koenig and Kunkel, 1990), each made up of a 
triple helix coiled coils giving dystrophin a more flexible linker like structure rather than a 
solid rod domain. Dystrophin contains multiple domains each with unique binding 
partners such as actin and a multitude of DAPC core proteins (figure 11). The two actin 
binding domains are located at the N-terminal (Rybakova et al., 1996) and within the 11-
15 domain of the Spectrin like repeats (Amann et al., 1998). Dystrophin contains a 
binding domain at the end of the 24th Spectrin like repeat for the transmembrane 
receptor protein β-dystroglycan (Jung et al., 1995), that with its glycosylated α-
dystroglycan partners mediate the connection between ECM ligands such as Laminin 
and the DAPC. 
Dystrophin also contains binding domains for two adaptor proteins Syntrophin (Yang et 
al., 1995b) and α-dystrobrevin (Sadoulet-Puccio et al., 1997), which link dystrophin to 
the tetrameric transmembrane sarcoglycan proteins. Syntrophin acts by binding to 
dystrophin and recruiting multiple signalling proteins to the DAPC, such as nNOS (Hillier 
et al., 1999) and Grb2 (Oak et al., 2001).  
α-dystrobrevin like syntrophin can recruit signalling and structural proteins to the DAPC 
such as Grb2 (phospho-dependent), α-catulin (phospho-independent) (Gingras et al., 
2016) and importantly binds to transmembrane sarcoglycans (Yoshida et al., 2000). 
Sarcoglycans appear to strengthen the DAPC through intracellular interaction with α-
dystrobrevin and extracellular interactions with α-dystroglycan through a mediating 
protein called Biglycan (Bowe et al., 2000; Rafii et al., 2006). 
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Sarcoglycans are also associated with another transmembrane protein Sarcospan 
(SSPN). Although the role of the SSPN is currently unknown in the DAPC, absence of 
SSPN causes autosomal recessive limb girdle muscular dystrophies which cause 
muscular atrophy in the hip and shoulder areas.  
All these interactions maintain and regulate the DAPC integrity and disruptions in many 




Figure 11-Dystrophin associated protein complex (DAPC) complex interaction with extracellular 
matrix mainly composed with Laminin and Collagen VI across the Sarcolemma membrane. Actin 
binding domain (ABD), dystroglycan binding domain (DBD), syntrophin binding domain (SBS), coiled 
coil domain(CC).α/β-Dystroglycan (α-DYS,β-DYS), neuronal nitric oxide synthase (nNOS), Sarcospan 




α-Catulin is an 82 kDa adaptor/signalling protein associated with the DAPC where it 
aids in the localisation and stability of the DAPC alongside acting as a regulatory 
signalling protein for the complex. α-catulin binds numerous DAPC core proteins such 
as α-and β-syntrophin, dystrophin, utrophin (Lyssand et al., 2010) and α-dystrobrevin, 
its structure and many binding partners have shown that α-catulin plays a larger role in 
protein localisation and cellular signalling not only in the DAPC.  
α-Catulin is mainly comprised of three main domains an N-terminal α-catulin head 
(ACH) (1-283), a middle-coiled coil domain (307-528, CC) and a C-terminal α-catulin tail 




α-Catulin can bind to many DAPC core proteins, but it is the association with one 
specific isoform of α-dystrobrevin, α-dystrobrevin-1 contributes to DAPC localisation and 
stability. α-dystrobrevin-1 contains an additional 176 amino acid extension at its c 
terminal which contains three regulatory tyrosine residues which are required to bind 
proteins such as Grb2 and α-catulin (Gingras et al., 2016). α-Catulin binding to α-
dystrobrevin-1 is phospho-independent, its binding region has been mapped to the very 
C-terminal of α-dystrobrevin-1 (468-590) a region not found in other α-dystrobrevin 
1-283 533-731 307-529 
Figure 12-Full length α-Catulin domain boundaries of the ACH (blue), middle coiled coil domain 






isoforms and the ACH (1-377). This association between α-dystrobrevin-1 and α-catulin 
has been shown to be vitally important in the localisation and stabilisation of the DAPC 
to the cell membrane, although complexes can form from DAPC proteins they are 
dispersed and not localised at costameres or NMJs (Oh et al., 2012). α-catulin has also 
been shown to increase sensitivity of DAPC associated α1D-adrenergic receptors, key 
in cardiovascular functions such as blood pressure and vascular integrity and 
maintenance, It does this by recruiting effector proteins into the DAPC enhancing its 
role as a membrane associated signalling hub (Lyssand et al., 2010). 
α-Catulin aids the localisation of calcium-dependent potassium (BK) channel SLO-1, 
channels important in the regulation of action potentials. In muscle SLO-1 channels are 
associated to the DAPC through a mediator protein SLO-1 interacting protein (ISLO-1) 
which binds through a PDZ domain to syntrophin (Kim et al., 2009). α-catulin knockouts 
showed a lack of SLO-1 localisation indicating α-catulin’s role in DAPC stabilisation and 
recruitment. In neurons however α-catulin aids in SLO-1 localisation but through an 
independent method not linked to the DAPC (Abraham et al., 2010). 
α-catulin acts as a scaffold for the Rho specific guanine nucleotide exchange factor Lbc 
with α-catulin (34-524) binding to Lbc (418-651) allowing α-catulin to regulate Rho 
signalling, which is important in cell actin/myosin based adhesion, apoptotic genes and 
cell differentiation (Park et al., 2002).  
As α-catulin acts as a scaffold for Rho signalling its presence in the cell has been shown 
to increase migration significantly and siRNA knockouts of α-catulin show diminished 
motility. α-catulin interestingly has also been linked to neural tube closure in 
morphogenesis, its association with the Rho signalling pathway and in particular actin 
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and phosphorylated myosin Light Chain 2 (P-Mlc2) have meant α-catulin depletion from 
mouse embryonic stem cells (ES) leads to failure of neural tube closure and death very 
early in embryogenesis at day E10.5 (Karpińska et al., 2020). 
α-Catulin additionally binds through a region in its tail domain (647–734) to Ik-Bb (466-
756), Ik-Bb being an inhibitor of the Nf-Kb family of transcription factors (Wiesner et al., 
2008). The Nf-Kb family having control over a wide range of genes including ones for 
,adhesion, cell motility, cell survival, differentiation, and some adaptive and innate 
immune response genes.  
This crosstalk between the Rho signalling pathway and the NF-Kb pathway has been 
linked to α-catulins role in tumorigenesis, notably in Melanomas and Squamous cell 
carcinomas (Cao et al., 2012; Kreiseder et al., 2015; Zhang et al., 2016). α-Catulin 
knockouts have been seen to arrest cell proliferation and induce senescence (Fan et al., 
2011) alongside being found to be highly expressed at the tumour invasion front (Cao et 
al., 2012). This contributes to tumour cells transformation into a more mesenchymal 
state indicating α-catulin as an oncoprotein.  
While α-catulin has been mostly associated with the DAPC, it plays a larger role in 
actin/actomyosin reorganisation and gene regulation in the cell regarding cell motility 
and survival. Its homology to vinculin and α-catenin (Janssens et al., 1999) may reveal 
additional binding interactors and perhaps indicate α-catulin has a larger role in the 






1.7.3 Vinculin Superfamily-Vinculin/α-Catenin/α-Catulin 
Vinculin shares structural and sequence homology with α-catenin (Identity 22.2% 
Similarity 36.4%) and α-catulin (Identity 17.6% Similarity 34.0%), α-catenin and α-catulin 
themselves share higher levels of homology (Identity 24.5% Similarity 40.6%) using 
Emboss water sequence alignment (Madeira et al., 2019). α-catenin and α-catulin are 
more closely related to each other phylogenetically with vinculin being more distantly 
related (figure 13) (Dereeper et al., 2008). All three proteins are associated with 
membrane associated adhesion/signalling complexes with vinculin in FACs, α-catenin 
and vinculin being associated in cadherin complexes (Watabe-Uchida et al., 1998) and 
α-catulin with the DAPC.  
Several of vinculins domains appear to be shared between α-catenin and α-catulin, with 
notable exceptions as seen in the multiple sequence alignment (MSA) using T-coffee 
(figure 14) (Di Tommaso et al., 2011). α-Catenin shares all vinculins domains except for 
the VD2 domain, with α-catulin lacking the VD2 and VD4 domains (figure 15). 
Secondary structure prediction using PSIPRED for both ACH and VD1 secondary 
structures shows that both the share 8 helices structure as seen in VD1 (Note PSIPRED 
shows 8 helices for VD1 and ACH but from X-ray structures VD1 is known to have 7 
helices not 8). The tail domains of both α-catulin and vinculin also share the 
characteristic 5 helices pattern making up the 5-helix bundle (Jones, 1999) (figure 16). 
 
Figure 13-Phylogenetic tree of mouse (Mus musculus) vinculin, α-catenin, α-catulin and Paxillin 
(outgroup) indicating that all three-show high evolutionary homology but that vinculin is a more distant 





                                                                                          BAD AVG GOOD 
sp|Q64727|VINC_       1 MP-----------VF-----------------HTRTIESILEPVAQQISHLVIMHEEGEVDGK   35  
sp|P26231|CTNA1       1 MT-----------AVHAGNI-NFKWDPKSLEIRTLAVERLLEPLVTQVTTLVNTNSKGPSNKK   51  
sp|O88327|CTNL1       1 MAASPVPGGGGAGAVHSSNAAGFTFDS-GLEIRTRSVEQTLLPLVSQITTLINHKDNTKKSDK   62  
  
sp|Q64727|VINC_      36 AIPDLT--APVAAVQAAVSNLVRVGKETVQTTEDQILKRDMPPAFIKVENACTKLVQAA----   92  
sp|P26231|CTNA1      52 RGRSKKAHVLAASVEQATENFLEKGDKIA--KESQFLKEELVVAVEDVRKQGDLMKSAA----  108  
sp|O88327|CTNL1      63 TLQAIQ--RVGQAVNLAVGRFVKVGEAIA--NENWDLKEEINIACIEAKQAGETIASLTDVTK  121  
 
sp|Q64727|VINC_      93 -QMLQSDPYS--VPARDYLIDGSRGILSGTSDLLLTFDEAEVRKIIRVCKGILEYLTVAEVVE  152  
sp|P26231|CTNA1     109 -GEFADDPCS--SVKRGNMVRAARALLSAVTRLLILADMADVYKLLVQLKVVEDGILKLRNAG  168  
sp|O88327|CTNL1     122 RSHLESDGQVTILTDKTGVVQAARLLLSSVTKVLLLADRVVIKQIVTSRNKILATMERLEKVN  184  
  
sp|Q64727|VINC_     153 TMEDLVTYTKNLGPGMTKMAKMIDERQQELTHQEHRVMLVNSMNTVKELLPVLISAMKIFVTT  215  
sp|P26231|CTNA1     169 NEQDLGIQYKALKPEVDKLNIMAAKRQQELKDVGNRDQMAAARGILQKNVPILYTASQACLQ-  230  
sp|O88327|CTNL1     185 SFQEFVQIFSQFGNEMVEFAHLTGDRQNDLKDEKKKARMAVARAVLEKGTMMLLTASKTCLR-  246  
 
sp|Q64727|VINC_     216 KNSKNQGIEEALKNRNFTVEKMSAEINEII---RVLQLTSWDEDAWASKDTEAMKRALASIDS  275  
sp|P26231|CTNA1     231 ----HPDVAAYKANRDLIYKQLQQAVTGIS---NAAQATASDDAAQ-----------------  269  
sp|O88327|CTNL1     247 ----HPSCESAHTNKEGVFDRMRVALEKVTEIVTDCRLSG-----------------------  282  
  
sp|Q64727|VINC_     276 KLNQAKGWLRDPNASPGDAGEQAIRQILDEAGKVGELCAGKERREILGTCKMLGQMTDQVADL  338  
sp|P26231|CTNA1     270 ---------------------------------------------------------------  269  
sp|O88327|CTNL1     283 ------------------------------------------------------E--------  283  
 
sp|Q64727|VINC_     339 RARGQGASPVAMQKAQQVSQGLDVLTAKVENAARKLEAMTN----SKQS----IAKKIDAAQN  393  
sp|P26231|CTNA1     270 ---------------HQGGSG-GELAYALN--NFDKQIIVDPLSFSEERFRPSLEERL-----  309  
sp|O88327|CTNL1     284 -----TDSS-----SVSIFTGIKELKVNIE--ALRENVCFE----SKEN----LSAAL-----  321  
  
sp|Q64727|VINC_     394 WLADPNGGPEGEEQIRGALAEARKIAELCDDPKERDDILRSLGEIAALTSKLGDLRRQGKGDS  456  
sp|P26231|CTNA1     310 ---------------------------------------------------------------  309  
sp|O88327|CTNL1     322 ---------------------------------------------------------------  321  
  
sp|Q64727|VINC_     457 PEARALAKQVATALQNLQTKTNRAVANSRPAKAAVHLEGKIEQAQRWIDN-PTVDDRGVGQAA  518  
sp|P26231|CTNA1     310 -------------------------------------ESIISGAALMADSSCTRDD-------  328  
sp|O88327|CTNL1     322 -------------------------------------EAVLEHVEDFTDSAYTSHE-------  340  
 
sp|Q64727|VINC_     519 IRGLVAEGHRLANVMMGPYRQDLLAKCDRVDQLTAQLADLAARGEGESPQA-----RALASQL  576  
sp|P26231|CTNA1     329 ------------------RRERIVAECNAVRQALQDLLSEYMGNAGRKERS--DALNSAIDKM  371  
sp|O88327|CTNL1     341 ------------------HRERILELSSQARTELQQLLSVWMQTQSRKTKSAAEELELTVLKI  385  
 
sp|Q64727|VINC_     577 QDSLKDLKAQMQEAMTQEVSDVFS--DTTTPIKLLAVAATAPPDAPNREEVFDERAANFENHS  637  
sp|P26231|CTNA1     372 TKKTRDLRRQLRKAVMDHVSDSFL--ETNVPLLVLIEAAKN-----GNEKEVKEYAQVFREHA  427  
sp|O88327|CTNL1     386 SHSLDELRRELHCTAMQLAADLLKFHADHVVLKALKVTGVE-----GNLEALAEYACKLSEQK  443  
 
sp|Q64727|VINC_     638 GRLGATAEKAAAVGTANKSTVEGIQA-SVKTARELTPQVISAARILLRNPGNQAAYEHFETMK  699  
sp|P26231|CTNA1     428 NKLIEVANLACSISN-NEEGVKLVRM-SASQLEALCPQVINAALALAAKPQSKLAQENMDLFK  488  
sp|O88327|CTNL1     444 EQLVETCRLLRHISG-TEP-LEITCIHAEETFQVTGQQIISAAETLTLHPSSKIAKENLDVFC  504  
 
sp|Q64727|VINC_     700 NQWIDNVEKMTGLVDEAIDTKSLLDASEEAIKKDLDKCKVAMANIQPQMLVAGATSIARRANR  762  
sp|P26231|CTNA1     489 EQWEKQVRVLTDAVDDITSIDDFLAVSENHILEDVNKCVIALQEKDVDGLDRTAGAIRGRAAR  551  
sp|O88327|CTNL1     505 EAWESQMSDMATLLREISDVFE-----------------------------------GRRGER  532  
  
sp|Q64727|VINC_     763 ILLVAKREVENSEDPKFREAVKAASDELSKTISPMVMDA-----KAVAGNISDPGLQKSFLDS  820  
sp|P26231|CTNA1     552 VIHVVTSEMDNYEPGVYTEKVLEATKLLSNTVMPRFTEQVEAAVEALSSDPAQPMDENEFIDA  614  
sp|O88327|CTNL1     533 CDH---------------------------LSLPK----------------------------  540  
  
sp|Q64727|VINC_     821 GYRILGAVAKVREAFQ----PQE---PDFPPPPPDLEQLRLTDELAPPKPPLPEGE-VPPPRP  875  
sp|P26231|CTNA1     615 SRLVYDGIRDIRKAVLMIRTPEELDDSDFETEDFDV---RSRTSVQTEDDQLIAGQSARAIMA  674  
sp|O88327|CTNL1     541 -------------------------------------------------PTKNSAN-LKSLKP  553  
  
sp|Q64727|VINC_     876 PPPEEK-DEEFPEQKAGEVINQPMMMAARQLHDEARKWSSKGNDIIAAAKRMALLMAEMSRLV  937  
sp|P26231|CTNA1     675 QLPQEQ-KAKIAE--Q----VASFQEEKSKLDAEVSKWDDSGNDIIVLAKQMCMIMMEMTDFT  730  
sp|O88327|CTNL1     554 DKPDSEEQAKIAK--L----GLKLGLLSSDADCEIEKWEDEENEIVRHGRNMSRMAYSLYLFT  610  
  
sp|Q64727|VINC_     938 RGGSG--TKRALIQCAKDIAKASDEVTRLAKEVAKQCTDKRIRTNLLQVCERIPTISTQLKIL  998  
sp|P26231|CTNA1     731 RGKGPLKNTSDVISAAKKIAEAGSRMDKLGRTIADHCPDSACKQDLLAYLQRIALYCHQLNIC  793  
sp|O88327|CTNL1     611 RGEGPLKTSQDLIHFLEVFAAEGLKLTSSVQSFSKQLKDDDKLMLLLEI-NKLIPLCHQLQTI  672  
 
sp|Q64727|VINC_     999 STVKATML---GRTNISDEESEQATEMLVHNAQNLMQSVKETVREAEAASIKIRTDAGFTLRW 1058  
sp|P26231|CTNA1     794 SKVKAEVQNLGGELVVSGVD---SAMSLIQAAKNLMNAVVQTVKASYVASTKYQKSQGMASLN  853  
sp|O88327|CTNL1     673 TKTSLQSK------VFLKVD---K---CITKIRSMMTLVVQLLSLCYKLLKKMENNRWGSATN  723  
 
sp|Q64727|VINC_    1059 VRKTP------WYQ--------------------------------------- 1066 ---------- 
sp|P26231|CTNA1     854 LPAVSWKMKAPEKKPLVKREKQDETQTKIKRASQKKHVNPVQALSEFKAMDSI  906 ---------- 
sp|O88327|CTNL1     724 KDTMD------GQN---------------------------------------  731 ---------- 
  
Figure 14-T-Coffee: a web server for the MSA of Vinculin=VINC, α-catenin=CTNA1, α-catulin=CTNL1 
with vinculin domains overlaid, with added colour conservation. 
 










                                                                                  
 
In both the vinculin and α-catenin the tail has been shown to be directly involved in F-
actin binding (Rimm et al., 1995) and in the case of vinculin also participates in 
autoinhibition (Bakolitsa et al., 2004; Izard et al., 2004). The N-terminal VD1 domain of 
vinculin has been shown to bind to VBS present in talin, which aid in strengthening and 
regulating FACs. 
α-Catulin has been the least studied of the three in terms of biochemistry, the regions of 
high homology between α-catenin and vinculin in particular raises the possibility that α-




Figure 15-Domains appear to be shared between the three vinculin superfamily proteins, with α-
catenin lacking VD2 and α-catulin lacking both VD2 and VD4. Notably all three conserve the VD1,VD3 






   




This project aims to biochemically characterise α-catulin and determine whether α-
catulin shares binding partners associated with vinculin. Some possible interactions that 
are to be explored are, 
1) Can the ACH interact with VBSs present within talin’s helical bundles like VD1?  
2) Is it possible for the ACT to enable α-catulin to exist in an autoinhibited state 
through ACH interactions or possibly interact with VD1 domain of vinculin?  
3) Also, can the ACT domain interact with actin as is seen in both VT and α-
catenin? 







Figure 16-Secondary structure comparison using PSIPRED between VD1 (A) and the ACH (B), 
which show a conservation of eight α-helixes of similar length and also between the ACT (C) and 
the VT (D) which shows a conservation of five α-helixes again of similar length. 
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2 Materials and methods  
2.1 Preparation of calcium competent Dh10β cells 
DH10β cells were spread onto lysogeny Broth (LB) agar plate without antibiotics and left 
overnight at 37°C. A single colony was used to inoculate a 5 ml overnight culture of LB 
without antibiotics and left overnight shaking at 37°C. 2x 100 ml of LB were prepared in 
250 ml flasks and 1 ml of overnight culture was added to each flask (1:100 dilution) 
without antibiotic. These were incubated at 37°C 160 rpm until an optical density (OD)  
(set at 595 nm) of 0.6-0.8 was reached whereupon they were removed and placed on 
ice for 10 minutes. The cells were centrifuged at 700 x g (2510 rpm in a Hettich Rotanta 
460 R centrifuge) 4°C for 10 minutes, the supernatant was then removed, and the pellet 
resuspended in 10 ml of ice-cold Calcium/glycerol buffer (0.1 M CaCl2, 10% w/v 
glycerol, filter sterilised) and was left on ice for 15 minutes. The culture was centrifuged 
as above, and the cells resuspended in 1 ml of the ice-cold calcium/glycerol buffer. The 
cells were aliquoted into 40 µl aliquots in ice cold 1.5 ml Eppendorfs and flash frozen in 
liquid nitrogen and stored at -80°C. 
2.2 Molecular biology-PCR/cloning  
2.2.1 Primer design 
Several constructs were required to be subcloned into differing vectors, be it for aiding 
in solubility or for the requirements of the vector plasmid. Both restriction enzyme digest 
and Gibson assembly types of cloning were attempted, primers for each construct were 















Primer 5’-3’ (Reverse 
complementary) 
C. caviae TarP 
VBS1-3  


























Table 1-Primers designed for restriction digest cloning using the ApE primer design software. Each 
construct requires both forward 5’-3’ and reverse 5’-3’ reverse complementary primers designed 
around the restriction digest sites specified by each restriction enzyme. 
Table 2-Primers for Gibson assembly cloning  were designed using the ApE primer design 
software. Each construct requires four primers, two for the construct itself and two for the vector for 
which the construct is to be cloned into. The construct and vector each require forward 5’-3’ and 






















































































































α-catulin ‘VBS  



















2.2.2 PCR  
To amplify the insert and vector in the Gibson assembly case the DNA must be 
amplified using PCR, a 50 µl total mixture was used with the following components and 
placed in the thermal cycler (see table 3).  
 
The thermal cycling conditions for each construct remain constant apart from the 
















PCR mixture Components Volume µl (Final concentration) 
Pfu DNA polymerase 10x buffer with 
MgSo4 (Promega) 
5 (1x Final concentration) 
DNTP (Invitrogen) 1 (100 mM Each) 
Forward primer (IDT) 1 (Final concentration 100 µM) 
Reverse primer (IDT) 1 (Final concentration 100 µM) 
DNA template 1 (Final concentration 100 – 200 ng/µl) 
Pfu DNA polymerase (added after DNTPs) 
(Promega) 
1 (Final concentration 1.25µ/50µl) 
Sterilised water  40 
Table 3-The constituents of a PCR mixture, this is a standard protocol but changes to primer 
concentration can be made if unsuccessful. 
 
Table 3-The constituents of a PCR m xture, this is a standard proto ol but changes to primer 
concentration can be made if unsuccessful. 
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differing primer annealing temperatures and the length of the constructs with larger DNA 
sequences to copy (see table 4).  
 
Construct vector Initial 
denaturation 










73°c for 2 
min 




ACH       
(1-258) 




73°C for 2 
min 




ACH      
(1-258) 




73°C for 2 
min 
















73°C for 4 
min 
















73°C for 4 
min 












73°C for 2 
min 




Table 4-PCR stages and conditions for each construct, the pET151-avi-2I27-mR6-2I27-spy vector 
was used for each Gibson assembly construct and as required the same conditions for each 
construct. 
 
Table 4-PCR stages and conditions for each construct, the pET151-avi-2I27-mR6-2I27-spy vector 





















73°C for 2 
min 


























To visualise the amplified DNA products the samples were run on a 1% agarose gel 
which was made by mixing 0.6 g of agarose and 60 ml of 0.5x TAE buffer (50x TAE 50 
mM EDTA, 1 M Glacial Acetic acid and Tris 2 M) in a small conical flask and 
microwaved at full heat for 1 minute. This mixture was poured into a DNA gel box and 
1000x gel stain (Ultraviolet (UV) sensitive) was added alongside a comb to create the 
wells, the gel was left for 30 minutes to set. To run an DNA sample 6x DNA dye was 
added to the sample in a ~1:6 ratio of dye to sample and load the sample into the wells 
left by the combs. A DNA ladder was also run to verify the sizes of the DNA bands 
visualised by the gel.  
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The gel was run for 45 minutes using the TAE setting 50 hertz (Hz) and then visualised 
under a UV gel dock to observe the DNA bands. The amplified DNA may contain 
impurities from cross contamination and as such requires purification and cleaning. 
250 µl of PB buffer were added to the 50 µl PCR product and spun at 13k rpm (Thermo 
fisher 24x 1.5/2 ml rotor) in a QIAquick column for 60 seconds discarding the flow 
through. 750 µl of PE buffer was added to the QIAquick column and spun again for 60 
seconds and the flow through discarded, the column was spun again to remove any 
residual buffer. The column was then placed into a 1.5 ml Eppendorf and 50 µl of EB 







Component Final volume  Final concentration 
PCR DNA  X µl Variable 
Restriction buffer 10x 10 µl 1x 
Restriction enzymes   
NHEI 10 u/µl (Promega) 2 µl 20u 
SalI 10 u/µl (Promega) 2 µl 20u 
XHOI 10 u/µl (Promega) 2 µl 20u 
NDEI 10 u/µl (Promega) 2 µl 20u 
Sterilised DH2O Make up to 100 µl  
Table 5-Restriction digest conditions for each restriction enzyme  
 
Table 5-Restriction digest conditions for each restriction enzyme  
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The flow through now contained the purified PCR product, its concentration now be 
determined using a Nanodrop. For restriction digest cloning restriction enzymes are 
required to cleave the PCR vector and insert so that they able to be ligated together 
later. The digest mixtures were prepared in 0.5 ml Eppendorfs and mixed thoroughly as 
restriction enzymes tend to sit at the bottom of the Eppendorfs. The digest mixtures 
were left at 37°C for 3 hours, mixing them every hour to ensure the restriction enzymes 
have not settled (see table 5).  
To visualise the digests 15 µl of 6x DNA dye was added to the mixtures and loaded 
across 4-5 wells of the agarose gel and run and visualised as before. The DNA was 
extracted from the gel using a QIAquick Gel extraction kit following manufacturer’s 
instructions and run on an agarose gel to observe band size. 
2.2.3 Ligation  
The digested PCR vector and insert were ligated together using the components listed 
in table 6, the concentrations of both the vector and insert were measured using the 
Nanodrop, the insert to vector ratio should be roughly 3:1 although the ratios can be 
altered if needed (see table 6). The ligation mixture was then left at 4°C overnight, then 
the next day the mixture was transformed into DH10β E.coli cells as explained above. 
At the end of the next day a 5 ml LB + chosen antibiotic (100 mg/ml)+a single colony 
was left overnight, the next morning a QIAprep spin Miniprep Kit (Qiagen) miniprep was 
used to extract the DNA according to manufacturer’s instructions and the DNA stored at 
-20°C.The DNA was  tested through a test restriction digest or sent for Sanger 




2.2.4 Gibson assembly  
Gibson assembly is a cloning technique that does not rely on specific restriction sites to 
enable the insert to be ligated into the new vector. Gibson uses multiple overlapping 
DNA fragments in this case two for each of the insert and vector alongside three 
enzymes T5 Exonuclease, Phusion DNA Polymerase and Taq DNA Ligase to fully ligate 
the insert into the new vector. Gibson assembly was attempted on the constructs listed 
in table 2, using the Gibson Assembly® Protocol (E5510) (NEB) following the 
manufacturer’s instructions. 
2.3 Cell culture 
2.3.1 Expression of recombinant polypeptide constructs  
Both Ampicillin and isopropyl β-D-1-thiogalactopyranoside (IPTG) were used at a final 
concentration of 100 mg/L from 1000x stock 0.2 µm filter sterilised. 
To express all the recombinant protein constructs (see table 7) 2 µl of DNA was added 
to 20 µl of BL21(DE3) competent E.coli cells and left on ice for 30 minutes. The BL21 
Component Volume  Concentration 
T4 DNA ligase 3 u/µl (Promega) 1 µl 3 u 
10x Ligase buffer (Promega) 1 µl 1X 
Insert  Variable Variable 
Vector Variable Variable 
Sterilised DH2O Make up to 10 µl  
Table 6-Ligation conditions, each construct will have differing DNA concentration depending on how 
successful the PCR was. A ratio of 3:1 insert to vector should be used and altered if unsuccessful. 
 
Table 6-Ligation conditions, each construct will have differing DNA concentration depending on how 
successful the PCR was. A ratio of 3:1 insert to vector should be used and altered if unsuccessful. 
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cells were placed in a 42°C water bath for 40 seconds and placed back on ice for 2 
minutes. 200 µl of LB was added to the BL21 cells and left at 37°C for one hour. 100 µl 
of the BL21 cells can be plated onto LB Agar plates (10 g tryptone,5 g yeast extract 5 g 
NaCl,15 g agar made up to 1 litre with Milli Q water) with ampicillin for antibiotic 
selection and left in a non-shaking incubator overnight at 37°C. The remaining 100 µl of 
BL21 cells can be added to 10 ml of LB in a 50 ml falcon tube containing ampicillin at a 
final concentration of 100 mg/l and incubated at 37°C 160 rpm in a shaking incubator 
overnight. 750 µl of overnight LB was added to 300 µl of 60% glycerol stock, vortexed 
and stored at -80°C. The remaining 9.25 ml of overnight  starter culture can be used to 
inoculate two 500 ml autoclaved LB flasks. 
  
Constructs  Residues Plasmid 
Mouse VD1  1-258 pET151 
Mouse VD1 A50I 1-258 pET151 
Mouse VD1 P15L 1-258 pET151 
Mouse VD1 W253X 1-252 pET151 
Mouse ACH  1-283 pET151 
Mouse ACT  533-731 pET151 
Mouse VTΔlinker  879-1066 pET151 
TarP VBS1-3 (C. caviae) 745-868 pET151 
TarP VBS1-3 GST   
(C. caviae) 
745-868 pGEX 
Table 7-Recombinat polypeptide constructs which were transformed into BL21(DE3) E.coli cells 
and glycerol stocks made for storage at -80°C. 
 
Table 7-Recombinat polypeptide constructs all of which were transformed into BL21(DE3) E.coli 
cells and glycerol stocks made for storage at -80°C. 
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2.3.2 Growth of cell cultures 
Ampicillin was added to autoclaved LB flasks and 4-5 ml of overnight LB starter culture 
was used to inoculate 500 ml of LB. These were incubated at 37°C 160 rpm for 
approximately 4 hours, checking the OD595 once per hour using a spectrophotometer 
until OD595 0.6-0.8 was achieved. Once reaching OD595 0.6-0.8, IPTG was added to the 
flasks to induce protein production. 500 µl samples were taken once an OD595 of 0.6-0.8 
was reached and again each hour for 3 hours. Each sample was centrifuged for five 
minutes at 13k rpm (Thermo fisher 24x 1.5/2 ml rotor) and the supernatant discarded, 
50 µl of reducing sample buffer (RSB) was added and heated at 90°C for 3-5 minutes 
and placed in a freezer at -20°C or room temperature to be used for Sodium dodecyl 
sulphate (SDS) Polyacrylamide gel electrophoresis (PAGE) analysis. 
2.3.3 Harvesting of cell cultures  
After the induction period the cultures were poured into 500 ml centrifuge tubes and 
spun at 2831 x g (4000 rpm in a Beckman JA-10 rotor) for 15 minutes at 4°C. The 
supernatant was removed, the bacterial pellets were resuspended in 25 ml of an 
appropriate buffer and stored in a 50 ml falcon tube at -20°C. 
2.3.4 Isotopically labelled protein expression 
Samples that that were to run be in multidimensional NMR experiments were required 
to be isotopically labelled with 15N Ammonium chloride. The cells were required to be 
grown in 2M9 minimal media (see table 8). 
Table 8-(Top) Components of the 10x M9 salts, (bottom) Composition of M9 minimal media for 
isotopic protein expression. 
 
Table 8-(Top) Components of the 10x M9 salts,(bottom) Composition of M9 minimal media for 
isotopic protein expression. 
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Composition of 10x M9 salts solution pH 7.2 Autoclaved 






Composition of M9 minimal media  0.2 µm sterile filtered  
Component  ml of solution per L of medium  
Milli-Q water (autoclaved) 887 
10x M9 salts  100 
1M MgSO4 (autoclaved) 1 
0.1M CaCl2 (Autoclaved) 1 
BME vitamins  1 
Glucose  4g per litre 
 
To maximise the growth of cells and to reduce the overall labelled compound used a 
condensation method was used that utilised the growing of unlabelled cells which were 
then condensed and transferred for growth in labelled media. A 4:1 condensation ratio 
of unlabelled media to labelled was used. 2x 10 ml Unlabelled LB overnight cultures 
were set up as previously mentioned with a scraping of the protein of interest glycerol 
stock alongside ampicillin. 5 ml of overnight culture was added per 500 ml autoclaved 
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LB media containing ampicillin. The cells were placed in an incubator at 37°C 160 rpm 
until an OD595 of between 0.6-0.8 was reached. Once the OD595 was reached the cells 
were centrifuged (3000 x g, 5 min at 4 °C) and then resuspended in 200 ml 10x M9 salts 
solution, centrifugation was repeated to wash the bacterial pellets of any remaining LB. 
The pellet was resuspended in 1 L of M9 minimal media and 1 g of 15N Ammonium 
chloride (NH4Cl) was added, (Note the NH4Cl was purposely not included in the 10x M9 
salts solution as it would require 11 g instead of 1 g, poignant if only performing limited 
numbers of experiments). The resuspended cells were left to acclimatise in M9 minimal 
media for 1 hour at 20°C, IPTG was then added, and the cells left incubating for 
approximately 15-20 hours at 18°C 160 rpm. Harvesting of the cells was performed as 
previously mentioned and the cells were resuspended in 25 ml of appropriate buffer and 
stored at -20°C. 
2.3.5 Lysis of cells by sonication 
The resuspended frozen bacterial pellets were thawed and lysed using 5 rounds of 
sonication using 30 second pulses at an amplitude 50% (14 Amps) for 5 minutes while 
continually being kept on ice. Length of sonication time may be in/decreased depending 
on the density of the bacterial cell pellet, but caution when increasing as overheating the 
cell lysate can occur degrading any protein present. Post sonication the lysed cells are 
poured into 50 ml centrifuge tubes and spun at ~48,000 x g at 4 °C for 30 min. The 
supernatant was stored in a 50 ml falcon whilst the bacterial pellet was discarded, 500 




2.4 Protein purification 
2.4.1 Nickel ion affinity chromatography 
2.4.2 Nickel Batch method  
Nickel ion Affinity chromatography was used to purify any constructs tagged with a 
histidine tag (His-tag). HisPur™ Ni-NTA Superflow agarose slurry beads were added to 
a 50 ml falcon tube and washed with 20 ml of Nickel buffer A (20 mM tris, 500 mM 
NaCl, 20 mM imidazole pH 8) and centrifuged at 700 x g (2510 rpm in a Hettich Rotanta 
460 R centrifuge) at 4°C for 2 minutes. Using a ratio of 1 mL HisPur™ Ni-NTA 
Superflow agarose slurry per litre of bacterial culture. The soluble cell lysate was added 
to the beads and left on a rocker to incubate for 20 minutes at room temperature, then 
centrifuged at 700 x g (2510 rpm in a Hettich Rotanta 460 R centrifuge) at 4°c for 3 
minutes. The supernatant was removed, and the pellet resuspended with 20 ml of 
Nickel buffer A and centrifuged at 700 x g (2510 rpm in a Hettich Rotanta 460 R 
centrifuge) at 4 °c for 3 minutes. This process was repeated five times and 
subsequently once with wash buffer (20 mM Tris, 500 mM NaCl, 50 mM imidazole pH8). 
After this final wash 10 ml of the supernatant was kept and the rest discarded, the 
beads were resuspended in nickel buffer A and poured into an empty gravity flow 
column (Bio-Rad).The flow through may be collected and a sample taken to run on an 
SDS-page gel to ensure the protein of interest hasn’t been lost after the higher 
imidazole wash buffer. Nickel buffer B (20 mM Tris, 500 mM NaCl, 500 mM imidazole 
pH8) was added to the column and three 1 ml elutions were collected. Throughout the 
batch method samples were taken at specific steps for further SDS-PAGE analysis, 1, 
2) after first Nickel buffer A wash both the supernatant and beads, 3, 4) after fifth Nickel 
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buffer A wash both the supernatant and beads, 5) after Wash buffer just supernatant 
and 6, 7, 8) each of the three 1 ml elutions. 
2.4.3 Immobilised Nickel ion affinity chromatography 
Nickel ion purification was also performed using an ÄKTA fast protein liquid 
chromatography (FPLC) system. Using the FPLC system a 5 mL HisTrap HP column   
was washed and equilibrated using Nickel buffer A and Nickel buffer B. The sample 
supernatant was loaded onto the column using a peristaltic sample pump and 
subsequently washed with 20 ml of Nickel buffer A. An imidazole gradient of Nickel 
buffer B was used to gradually reach a Nickel buffer B percentage that eluted the 
protein of interest. Samples of each elution can be taken and run on an SDS-PAGE for 
analysis if the elution peaks appear undefined or to check purity. The 5 mL HisTrap HP 
column was then washed with Nickel buffer A and stored in 20% ethanol.  
2.4.4 Dialysis 
If the proteins are required to be further purified through ion exchange chromatography 
dialysis into a lower salt buffer was required. The elutions were dialysed using Thermo 
Scientific SnakeSkin dialysis tubing (7000 MWCO) into five litres of Q-buffer A (20 mM 
Tris-HCl, 50 mM NaCl pH8) for proteins with an isoelectric point (pI) below 7, or S buffer 
A (20 mM phosphate, 50 mM NaCl, pH 6.5) for proteins with a pI of above 7. These 
were left overnight at 4°C with stirring, additionally if the His-tags were to be cleaved a 





2.4.5 PD-10 desalting column 
An alternative to lengthy dialysis is a buffer exchange using a pd-10 desalting which can 
be used to quickly exchange a protein from one buffer to another, especially in 
removing one from a high imidazole after a nickel ion purification. A PD-10 column was 
equilibrated with 25 ml of an appropriate buffer and the flow through discarded. 2.5 ml of 
sample was added to the column (if under 2.5 ml use buffer to make up to 2.5 ml) and 
the flow through discarded. 3.5 ml of the buffer to be exchanged into was added and the 
flow through collected. 
2.4.6 Batch GST-purification 
Protein constructs containing a Glutathione S-transferase (GST) tag were purified using 
a batch method like the previously mentioned hit-tag method. Per 1 litre bacterial culture 
~1 ml of Pierce™ Glutathione Superflow agarose slurry was added to a 50 ml falcon 
tube and the beads washed with 20 ml of 1x phosphate buffered saline (PBS) (10x 
stock concentration 100 mM NA2HPO4, 18 mM KH2PO4, 1.4 M NaCl pH 7.4) by mixing 
gently. This was centrifuged at 700 x g (2510 rpm in a Hettich Rotanta 460 R centrifuge) 
for 3 minutes at 4°C and the supernatant discarded. 
The soluble cell lysate was then added to the washed beads and left to incubate for 1-2 
hours at room temperature or if the protein is prone to degradation the same incubation 
period can be done at 4°C. Once fully incubated the sample is centrifuged at 700 x g 
(2510 rpm in a Hettich Rotanta 460 R centrifuge) for 3 minutes at 4°C and the 
supernatant removed, a sample of the supernatant was taken at this point for SDS-
PAGE analysis. 25 ml of 1x PBS was added and the sample was centrifuged at 700 x g 
67 
 
(2510 rpm in a Hettich Rotanta 460 R centrifuge)) for 3 minutes at 4°C and the 
supernatant removed. This wash step was repeated 5 more times and a sample was 
taken after the last wash of both the supernatant and beads for SDS-page analysis. The 
beads were resuspended in 1x PBS and were now ready to use for a GST-pulldown 
experiment if required. If the GST tag is to be removed from the sample, a TEV 
protease was added and left agitating overnight at 4°C. The sample was then poured 
through a gravity column and the flow through collected as this now contained the 
protein of interest if the TEV protease had fully cleaved the protein from the beads. A 
sample for SDS-PAGE analysis was taken to confirm this. Note the TEV should also be 
in flow through. 
2.4.7 Ion exchange chromatography  
FPLC automated ion exchange chromatography was also performed to separate the 
proteins based on their charge. Each individual protein will have a unique pI at which 
the protein will have a net charge of zero. Inputting the amino acid sequence into 
ExPASy ProtParam (Wilkins et al., 1999) allowed the pI to be determined for each 
protein. If the protein had a pI of <7 then a negatively charged cation exchanger (Q-
column) was used with Q-buffer A (20 mM Tris , 50 mM NaCl, pH8) and Q-buffer B (20 
mM Tris, 1M NaCl,pH8). If the pI was 7> then an anion exchanger (S-column) was used 
with S-buffer A (20 mM phosphate pH 6.5, 50 mM NaCl) and S-buffer B (20 mM 
phosphate pH 6.5, 1 M NaCl).Note for proteins with a pI above 8 which were used for 
crystallography a MES-buffer A (20 mM MES-Hydrate pH 6.5, 50 mM NaCl) and MES-
buffer B (20 mM MES-Hydrate pH 6.5, 1 M NaCl) was used to exclude phosphate ions. 
A Q-column can remove the TEV-protease and cleaved His-tag if used as they both 
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flow into waste and do not stick to the column. An S-column binds TEV-protease and as 
such the peaks were analysed and run on a gel to determine which fractions contain 
just the protein of interest.  
Using the same FPLC procedure as the immobilised Nickel chromatography, the protein 
was loaded onto the column and an increasing salt concentration that eluted the protein 
of interest in 3 ml fractions. The fractions were analysed using SDS-PAGE. The proteins 
were either dialysed/buffer exchanged into another buffer, aliquoted out to be used or 
flash frozen with and kept at -20°C. 
2.4.8 SDS-PAGE 
10% SDS-PAGE gels of samples collected were run with SDS MOP buffer in a 
SureLock gel tank, set at 200 volts and 400 amps for 1 hour. Gels were stained with 
Coomassie blue and left for 1 hour, Coomassie blue destain was added to counterstain 
the gels and left for 1 hour. Coomassie destain was repeated twice before visualizing 
the gels.  
2.5 Biochemical/biophysical assays  
2.5.1 Fluorescently Labelling peptides 
Peptides were labelled with fluorescein for use in fluorescence polarisation 
experiments.100 µM of the peptide was mixed together with 25 µl of fluorescein-5-
maleimide dye, 5 µl TCEP (1 M stock), 2.5 µl of 20% Triton X and made up to 1 ml with 
1x PBS. The mixture was covered in foil to block UV light and then left mixing for 2 
hours at room temperature. A PD-10 column was equilibrated with 25 ml of 1x PBS and 
the labelled peptide was added, and the excess equilibration buffer allowed to flow 
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through. 2.5 ml of 1x PBS was then added to elute the labelled peptides and the flow 
through was collected, the labelled peptides typically eluted after the first 1 ml. The 
labelled peptides were prepared in 10 µl aliquots and flash frozen using liquid nitrogen 
and stored at -20°C. 
2.5.2 Size exclusion chromatography-Gel filtration 
Size exclusion chromatography (SEC) is a technique that allows separation of 
molecules based primarily on the molecular weight, shape, and hydrodynamic 
properties of the molecule. The Hydrodynamic properties of a molecule being solvent 
associated with the molecule. SEC works on the principal that molecules are passed 
through a column filled which contains a gel matrix of porous beads that have a very 
specific size arrangement. The separation of molecules occurs through the porous 
beads as large molecules do not diffuse into the porous matrix and are eluted early on, 
whereas small molecules diffuse into the porous matrix and are retained for longer 
periods resulting in later elution. Consequently, larger molecules being eluted before 
smaller molecules enables the molecules to be separated by size. Gel filtration is a 
specific type of SEC which uses a hydrophilic filled column with an aqueous mobile 
phase to elute the molecules. 
Gel filtration was performed using a Superdex-200 size exclusion chromatography 
column (GE healthcare). 1x PBS buffer was set at a flow rate of 0.75 ml min-1 to 
equilibrate the column, 500 µl VD1 and ACT samples were both run individually at 56 
µM. VD1 and ACT both at 56 µM were then incubated together at room temperature for 
45 mins in a 1:1 ratio before being loaded. 
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2.5.3 Size exclusion chromatography with multiangle light scattering 
To analyse the stoichiometry of the of the TarP VBS1-3 with VD1 SEC with multiangle 
light scattering (SEC-MALS), utilising SEC as explained above to separate the proteins 
according to size whilst the MALS detects light scattered by the proteins after they are 
eluted from the column allowing the proteins precise molecular weights to be 
determined. This technique can be used for determining the stoichiometry of multiple 
monomers binding to a single secondary protein. 
The Superdex-200 size exclusion chromatography column (Ge healthcare) and MALS 
machine (Viscotek SEC-MALS 9 and Viscotek RI detector VE3580 (Malvern 
Panalytical) was equilibrated with 1x PBS buffer at a flow rate of 0.75 ml min-1, the 
making sure the flow is continuous for at least three hours before running any samples 
to allow MALS and RI (refractive index) signals to stabilise. 40 µM VD1 was run 
singularly and then with TarP VBS1-3. VD1 and TarP VBS1-3 were then incubated for 
one hour at room temperature. (The concentration of the TarP VBS1-3 was estimated 
based on protein concentration determined on agarose gels (as it contains no UV 
absorbing residues) alongside serial dilutions of VD1). This was done as to achieve a 
1:3 ratio between TarP VBS1-3 and VD1 respectively to allow the full extent of the 
stoichiometry of the TarP VBS1-3 VD1 binding sites to be apparent. 40 µM VD1 was 
determined to be in excess of this 1:3 ratio  with TarP VBS1-3. Both samples were run 
at the same constant 0.75 ml and eluted in 500 ml aliquots. The elution profile was then 





2.5.4 GST-Pulldowns  
To identify any binding partners for a GST-tagged protein a technique known as a GST-
pulldown was attempted which utilised the Glutathione bound GST tagged proteins 
previously purified and a query protein to identify any interactions while the GST-protein 
is still attached to the Glutathione beads. If interactions are seen, different ratios 1:1, 1:2 
etc can aid in determining any stoichiometry in binding when it is shown a protein may 
have multiple binding sites for the same protein. 50 µl of the TarP VBS1-3 GST loaded 
beads in 1x PBS was mixed with 150 µl of VD1 in an Eppendorf at 5 µM 1:1 ratio, 10 
µM 1:2 and 1:3 15 µM, the 5 µM 1:1 ratio was predicted through optimisation with 
varying concentrations of VD1 to the TarP VBS1-3 GST on an SDS-page gel. The 
Eppendorfs were left to incubate on a rocker at 25°C for one hour. The samples were 
spun in a tabletop centrifuge at 700 x g (2510 rpm in a Hettich Rotanta 460 R 
centrifuge) for 5 minutes at 4°C and 50 µl of the supernatant was taken. The GST pellet 
was washed twice more with 1x PBS at 700 x g (2510 rpm in a Hettich Rotanta 460 R 
centrifuge)for 3 minutes at 4°C and the supernatant removed. A 10 µl sample of both 
the GST beads and the supernatant were taken and run of an SDS-PAGE as explained 
above.    
2.5.5 Circular Dichroism  
Far UV circular dichroism (CD) is an ideal technique for visualising secondary structures 
such as α-Helices, β-sheets, βTurns and random loops of proteins. The basis of CD is 
that proteins differently absorb right and left circularised polarised light through chiral 
chromophores that are present throughout amides groups along the polypeptide 
backbone of the protein. A proteins thermal stability can also be determined by 
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performing a melting curve, the change in CD signal can be followed over a temperature 
gradient. The binding of ligands to proteins can also be visualised as changes in protein 
secondary structure are evident in many binding events. 
Analysis of ACT and VTΔlinker using CD was performed on a JASCO J-715 
spectropolarimeter equipped with a JASCO PTC-423S temperature control unit. A Far 
UV CD spectrum was performed on both ACT and VTΔlinker at wavelengths 190-260 
nm. Each protein was run at 20°C, 4 µM concentration dissolved in 1x PBS. A 
temperature melting curve was performed at temperatures ranging from  20-90°C with 
1°C per minute increments. Both samples were blanked with 1x PBS buffer. All 
experiments were carried out using a 0.1 cm pathlength quartz cell. 
2.5.6 Nuclear Magnetic Resonance spectroscopy 
Nuclear magnetic resonance (NMR) is a technique that exploits the quantum nuclear 
spin properties of atoms when under a strong magnetic field. Using short 
radiofrequency pulses followed by relaxation periods it is possible to pass magnetisation 
from one nuclei to another and record the changes in environment. For 1D experiments 
the 1H present in the backbone and chemical groups found throughout the protein are 
recorded, each peak corresponding to a unique 1H environment. For 2D NMR 
experiments the protein is required to be isotopically labelled with either 15N or 13C. In 
15N labelled proteins each peak corresponds to a unique magnetic environment 
between the backbone amide 15N and 1H, alongside sidechain NH and NH2 groups. 
Changes in the environment be it denaturation or ligand binding can be seen by shifts in 




An 15N ACT sample was grown up using the condensation method of isotopically 
labelled proteins as explained above and purified using nickel ion affinity and ion 
exchange FPLC. The sample was dialysed into phosphate buffer (50 mM NaCl, 20 mM 
sodium phosphate, 2 mM DTT pH 6.5). The NMR spectra were obtained using a Bruker 
AVANCE III 600 MHz spectrophotometer with Cryo Probe set at 298K. A 450 µl ACT 
sample which included 5% D2O was added to a Shigemi NMR tube and run at 50 µM 
concentration. 1D and 2D heteronuclear single quantum correlation (HSQC) 
experiments were performed to analyse ACT. 
2.5.7 Fluorescence polarisation assays  
A fluorescence polarisation assay works on the basis that when a fluorescently tagged 
peptide is excited by polarised light the light that is emitted is also polarised. A 
fluorescently labelled protein in solution tumbles however and causes a drop in the 
emission of polarised light. If when in solution however the fluorescently tagged peptide 
binds to a protein the peptide will tumble at a reduced rate and as such an increase in 
polarised in one direction is detected. This change in polarisation alongside a series of 
increasing protein concentrations can enable binding affinities to be generated. 
Three peptides were coupled to a thiol reactive fluorescein tag to a C-terminal cysteine 
residue present in each peptide, the three peptides being paxillin LD2, TarP VBS1 and 
TarP VBS3. (Note TarP VBS2 peptide aggregated in solution so was not coupled). 
Paxillin_LD2    (NLSELDRLLLELNC)                      Homo sapiens residues 141-153 
TarP_VBS1 (LLEAARNTTTMLSKTLSKV-C)                 C. caviae residues 850–868  
TarP_VBS3 (DLHGAAKGVADSLSNLLQAATP-C)        C. caviae residues 745–766  
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The paxillin LD2 peptide were tested with the ACT and VTΔlinker sample and prepared 
in 1X PBS (140 mM NaCl, 100 mM Na2HPO4, 18 mM KH2PO4) and run at a stock 
concentration of 300 µM. TarP VBS1 and 3 were tested with VD1, prepared in 1X PBS 
and run at a stock concentration of 200 µM. 
Each sample was titrated in 1x PBS using a constant 1 µM concentration of fluorescein-
coupled peptide, with increasing protein concentration culminating in a final 100 µl final 
well volume. Each experiment was run at 25°C and in triplicate. The Data was recorded 
on a BMG LabTech CLARIOstar plate reader and the Kd calculated using GraphPad 
Prism software based on the one-site binding model.  
2.5.8 X-ray crystallography  
Multiple crystal screens were attempted for VD1 lethality rescuing mutants A50I, P15L, 
W253X and the ACT, all performed at room temperature, screened with concentrations 
ranging from 4-20 mg/ml and encompassing protein to peptide ratios (where applicable) 
between 1:1 and 1:3. Successful crystal formation conditions are listed below in table 9. 
All screens were processed using the Mosquito® XTal3 utilising a hanging drop vapour 
diffusion method.  
Vinculin W253X and Talin helix 50 complexes   
Crystal screening for the Vinculin mutant (Mus musculus) W253X-H50 (Mus musculus) 
complex were performed at room temperature, the W253X concentration at 214 µM inm 
(20 mM Tris, 50 mM NaCl, 1 mM DTT pH8) with Talin H50 at a concentration of 430 µM 















Screen Condition Diffraction 


































The mix was then left to incubate for 2 hours at room temperature. JCSG+ 96 well 
screening plates were used to identify optimal conditions for crystal growth and left for 
five days at room temperature (22°c). Crystals growth was observed in condition H7 
which was comprised of 0.2 M ammonium sulphate salt, 0.1 M Bis/tris, pH 5.5 with 25% 
w/v PEG 3350. A 24 well optimisation screen was prepared using the H7 condition 
varying the ammonium sulphate 0.1 M-0.2 M, the PEG 3350 25%-29% and pH 5.4-5.7. 
Table 9-Conditions for each successful crystal formation and if successfully diffracted at Diamond 
light source. 
 




Optimisation proved unsuccessful, so the crystals were taken from the JCSG+ 96  plate 
and cryoprotected in liquid nitrogen.  
Vinculin VD1 and TarP VBS3 complex  
Previously Crystal screening for the (Gallus gallus) VD1-TarP VBS3 (C.Caviae) 
complex had been performed and resulted in diffraction of the crystals. The crystal 
screenings were carried out at room temperature, the VD1 concentration was 500 µM in 
(20 mM Tris, 50 mM NaCl, 1 mM DTT pH8) with TarP VBS3 at 1500 µM in 1:3 protein to 
peptide ratio. The mix was then left to incubate for 2 hours at room temperature. JCSG+ 
96 well screening plates were used to identify optimal conditions for crystal growth and 
left for five days at room temperature (22°c). Crystal growth was observed in condition 
H3 which was comprised of no salt, 0.1 M Bis/tris, pH 5.5 with 25% w/v PEG 3350. A 24 
well optimisation screen was prepared using the H3 conditions varying the PEG 3350 
21%-31% and pH 5.3-5.6. Optimisation proved successful, crystals were taken from the 
optimisation plate and cryoprotected in liquid nitrogen. Note this set of crystals was 
produced with help from Dr.Austin whitewood. 
Both W253X-H50 and VD1-TarP VBS3 diffraction data was collected at Diamond Light 
Source (Didcot, UK) using beamline i04-1 and the data was automatically processed 
using autoPROC for W253X-H50 and Dials-Xia2 for VD1-TarP VBS3 which both utilise 
XDS, Pointless, Aimless and Staraniso for subsequent integration, scaling and merging 
of the collected data. Determination of both structures was carried out utilising PHASER 
molecular replacement using (PDB:4DJ9) for W253X-H50 and (PDB:3ZDL) for VD1-
TarP VBS3. The structures were manually remodelled and refined using COOT and 




3.1. Project 1:C.caviae TarP vinculin binding site structure and stoichiometry 
C.caviae TarP is unique among TarPs in that it has three VBSs, most other species 
having two or one. Here we have explored if all three VBS are required, if there is a 
hierarchy between them in terms of binding affinity and how important is each to the 
invasion process?  
TarP VBS3 binding data and structure were acquired and compared with the TarP 
VBS1 data (Whitewood et al., 2018). Also, the stoichiometry of the TarP VBS1-3 region 
binding to VD1 molecules was determined, also inadvertently giving some indications as 
to whether the TarP VBS2 may bind to VD1 as well. 
3.1.1 TarP VBS3 binds to VD1 with higher affinity than TarP VBS1 
To obtain TarP VBS3 binding data an in vitro FP assay was performed with TarP VBS1 
as a positive control and comparison. The TarP VBS3 peptide bound VD1 tightly with a 
Kd of 81 nM, binding with higher affinity than the TarP VBS1 peptide tested here at 223 
nM and also with the previous binding data for TarP VBS1 129 nM (Whitewood et al., 
2018). 
This higher affinity seen in TarP VBS3 may indicate that TarP VBS3 may have a more 
prominent role than stated previously (Thwaites et al., 2015) where the TarP VBS1 was 




3.1.2 Cloning TarP VBS 1-3 into pGEX GST vector 
TarP VBS1-3 in pET151 N-terminal His-tag vector appeared to aggregate after lysing 
the BL21 cells and optimisation using high concentration urea to alleviate the 
aggregation was unsuccessful. It was then subsequently successfully cloned into a 






Figure 17-FP binding data between VD1 and both TarP VBS1 and VBS3, the TarP VBS3 Kd 
value of 81 nM indicates it has a higher binding affinity than TarP VBS1 having Kd  value of 223 
nM. Data presented using GraphPad Prism software (SE values are shown in the legend), all 
experiments were run in triplicate and with two biological replicates. 
 
Figure 17-FP binding data between VD1 and both TarP VBS1 and VBS3, the TarP VBS3 Kd 
value of 81 nM indicates it has a higher binding affinity than TarP’s VBS1 having Kd  value of 223 
nM. All experiments were run in t iplicate and d ta presented using GraphPad Prism softwa e 
(SE values are shown in the legend).      
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3.1.3 GST-Pulldown using TarP VBS1-3 to determine stoichiometry of VD1 
binding  
C.caviae TarP contains three VBS and VBS1 and 3 have been shown to bind to VD1 
with high nanomolar affinity though FP, with VBS2 seemingly unable to stay in solution 
without aggregation. C.caviae TarP is unique in having three VBSs, as all other TarPs 
have one or two depending on the species, the stoichiometry of VD1 binding to 
C.caviae TarP is something that is unknown. By performing a GST pulldown with a 
determined 5 µM bead bound TarP VBS1-3 GST (MW 39 kDa) mixed with either 5 µM, 
10 µM or 15 µM VD1 (MW 29 kDa), would allow us to identify if the TarP VBS1-3 GST 
bound VD1 in a 1:1, 1:2 or 1:3 ratio. (Note the TarP VBS1-3 GST concentration was 
determined to be 5 µM by serial dilution of 5 µM, 10 µM, 15 µM VD1 against TarP 
VBS1-3 GST, see figure 18). This would allow the analysis of the number of VBSs  
 Talin 







Figure 18-SDS gel to determine the concentration of TarP VBS1-3 GST. Lane 1 protein ladder (PL), 
lane 2 TarP VBS 1-3 GST, lane 3-5 VD1 5 µM, 10 µM, 15 µM respectively and lane 6 talin R9 5 µM. 
TarP VBS 1-3 GST was determined to resemble the VD1 at 5 µM (lane3). Pulldown assay was 
performed with three biological replicates. 
 
Figure 18-SDS gel to determine the concentrations TarP VBS1-3 GST. PL, protein ladder. Lane 1 
TarP VBS 1-3 GST, lane 2-5 VD1 5,10,15 µM respectively and lane6 talin R9 5 µM. TarP VBS 1-3 
































that can be occupied at any one time, adding the possibility whether structural restraints 
restrict VD1 bindings. All protein concentrations in the GST-pulldown (figure 19) 
resemble the concentrations seen in figure 18. Viewing the GST-pulldown (figure 19), 5 
µM, 10 µM and 15 µM VD1 all appear in the bead samples when mixed with TarP 
VBS1-3 GST, indicating VD1 association with bead bound TarP VBS1-3 GST. The 10 
µM and 15 µM VD1 samples when mixed with TarP VBS1-3 GST additionally showing 
trace amounts of VD1 in the supernatant, indicating that they are possibly not exact 1:2 
and 1:3 ratios and the concentrations perhaps are slightly too high. However, the 
majority of VD1 is present in bead sample of TarP VBS1-3 GST mixed with the 15 µM 
VD1 concentration, which indicates that TarP VBS1-3 could possibly bind VD1 up to a 
potential 1:3 ratio, further attempts to optimise the concentration would still need to be 
Figure 19- SDS gel of GST-pulldown of TarP VBS1-3 GST with 5 µM, 10 µM and 15 µM VD1, 
alongside TarP VBS1-3 GST with 5 µM talin R9 (control) and washed glutathione beads (WGB) with 5 
µM VD1 (control). PL=protein ladder, BD=beads, SN=supernatant. Red arrow TarP VBS1-3 GST (39 
kDa), Black arrow VD1 (29 kDa) and green arrow talin R9 (17 kDa). Note VD1 kDa in beads appears 
lower down due to higher concentration present when compared to supernatant. Pulldown assay was 
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attempted. Controls of washed glutathione beads with 5 µM VD1 which showed VD1 in 
the SN and not in the BD indicating no interaction with the washed glutathione beads. 
Additionally, a control of bead bound TarP VBS1-3 GST with 5 µM talin R9 (MW 17 
kDa) was used as a negative control, R9 was found in the supernatant indicating no 
interaction with the bead bound TarP VBS1-3 GST. 
3.1.4 SEC-MALS analysis of the stoichiometry of VD1 binding to TarP VBS1-3 
To aid in confirming the stoichiometry between TarP VBS1-3 and VD1, a SEC-MALS 
assay was performed to more accurately determine how many VD1 monomers 
associate with the TarP VBS1-3. The SEC-MALS experiment will allow a visualisation of  
stoichiometry of VD1 binding to TarP VBS1-3 by analysing shifts in peaks to smaller 






















VD1 40um VD1 40µm+TarP VBS1-3
Figure 20- SEC-MALS data indicating the lack of association between the TarP VBS1-3 and VD1. 
Each VD1 sample was run 40 µm, although fluctuations in sample volume with the variation in peak 
height in between the VD1 apo and VD1+TarP VBS1-3 runs is present. SEC-MALS was performed 





complexes can be accurately determined to discover the stoichiometry of VD1 binding 
(figure 20).  
A 40 µM apo VD1 sample was run and is seen forming a characteristic double peak with 
the monomer eluting at ~24.5 ml and the dimer at ~23 ml. In the 40 µM VD1:TarP 
VBS1-3 mix the VD1 eluted at ~24.5 ml again although the dimer of VD1 at ~23 ml is 
not present, the peak itself is much larger than the VD1 sample and again the problem 
is attributed to over concentration the VD1:TarP VBS1-3 before loading. What is not 
seen however are any peaks at smaller retention volumes appearing from supposed 
VD1:TarP VBS1-3 complexes, while the TarP VBS1-3 has been seen to interact with 
VD1 in the GST pulldown section 3.1.3 that was when still attached to a GST tag. The 
lack of any complexes forming indicates that the TarP VBS 1-3 when cleaved from its 
GST tag as is the case here, may aggregate and as such not effectively bind VD1. The 
TarP VBS1-3 is a disordered protein, and a GST-tag was necessary for it to be soluble 
and able to be purified, by cleaving the GST-tag after purification may again render it 
insoluble. An attempt was made to use reduced glutathione to remove the TarP VBS1-3 
GST tagged protein from the Glutathione Superflow agarose slurry beads but was 
unsuccessful due to aggregation on addition of the reduced glutathione. While 
unsuccessful, a repeat of this experiment with optimisation in the removal of the TarP 
VBS1-3 GST tagged protein from the Glutathione Superflow agarose slurry beads 
leaving the GST tag attached, as well as controls of VD1:VT as positive control and 
VD1:talin R9 and VD1:apo GST tag as negative controls would give a more definitive 




3.1.5 VD1:TarP VBS3 crystal structure  
The VD1:TarP VBS3 was determined at 2.08 Å in a P21212 orthorhombic space group 
with 1 molecule being present in the asymmetric unit (Au) with a probability of 99% 
using Matthews coefficient. Using Pisa analysis, it was seen that 57.4% of the TarP 
VBS3 is buried in the complex interface with VD1, further details of validation and 
quality analysis can be seen in figure 20. The TarP VBS3 peptide has two residues 
proline 870 and cysteine 871 that are not visible in the electron density, due to being 
present in a disordered loop region. 
The TarP VBS3 can be seen to interact with VD1 in the same helical bundle insertion 
into the N-terminal helical bundle of VD1 as seen in talin VBSs. Helices α1 and α2 can 
be seen to be separated by the TarP VBS3 which then positions itself in the 
hydrophobic core of the N-terminal helical bundle of VD1 (figure 21). 
 
Figure 21-Structural statistics of the TarP VBS3-VD1 crystal structure as determined in CCP4i2 
REFMAC program. 
 




A Hydrogen bond is present between VD1 Glutamine 19 to TarP VBS3 serine 758 
which is mostly conserved between VBSs with regards to residue and bond distances 
(figure 22B).                                                                                                                          
The structure shows that hydrophobic residues line the primary interface side of the 
TarP VBS3 peptide and look to enable its tight association within the hydrophobic core 
of the helical bundle (figure 22A). Differences between the TarP VBS1 and 3 residues in 
this hydrophobic interface are present, TarP VBS1 appears to differ from TarP VBS3 at 
two key residues T857 and T864, which in TarP VBS3 are V753 and L760 at the same 
positions (figure 22 C, D, E). While TarP VBS1 has two other hydrophobic residues in 
its VBS namely L850 and L851, these are either not modelled with L850 due to being at 
the end of the peptide as such it’s difficult to determine precise orientation but is 
conserved so is most likely also important in binding much like its conserved residues in 
the same position in other VBS. L851 presence seems non-essential in binding as there 
is no consensus in that position among VBS . 
Figure 22-TarP VBS3-VD1 structure modelled in PyMOL showing the helical insertion of the TarP 
VBS3 peptide between the α1 and α2 helices of VD1. Interface residues side chains are modelled 
using the interfaceresidues.py script in PyMOL. 
 
Figure 22-TarP VBS3-VD1 structure modelled in PyMOL showing the helical insertion of the TarP 
VBS3 peptide between the α1 and α2 helices of VD1. Interface residues side chains are modelled 























                                                                                                                                                                                                                                                                                                                                                           
Figure 23-(A) TarP VBS3 hydrophobic residues interacting with the hydrophobic core of VD1. (B) 
Hydrogen bond between VD1 Q19 and TarP VBS S758. (C) Overlay of TarP VBS3 V753 (orange) 
and TarP VBS1 T857(red). (D) Overlay of TarP VBS3 L760 and TarP VBS1 T864.(E) TarP VBS3 and 
TarP VBS1 overlaid with all consensus residues labelled with side chains. 
Figure 23-(A) TarP VBS3 hydrophobic residues lining the hydrophobic core of VD1.(B) Hydrogen 
bond between VD1 Q19 and TarP VBS S758. (C) Overlay of TarP VBS3 V753 (orange) and TarP 
VBS1 T857(red). (D) Overlay of TarP VBS3 L760 and TarP VBS1 T864.(E) TarP VBS3 and TarP 


































































































































































































A methionine M860 is present in the TarP VBS1 but it is positioned away from the 
hydrophobic core interface. An additional hydrogen bond is present in TarP VBS1 
between VD1 S11 and TarP VBS1 R855 but is not seen in the TarP VBS3, this 
ubiquitously conserved residue appearing as either arginine/lysine/asparagine. 
However, although the residue is conserved this hydrogen bond is rarely seen in any 
VD1-VBS complexes and as seems unimportant in binding affinity. 
Comparing the TarP VBS1 and 3 structures, the inclusion of the extra two hydrophobic 
residues V753, L760 in TarP VBS3 which interact with the VD1 hydrophobic core 
appear to be the cause for the increase in affinity seen in figure 17.   
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3.2. Project 2: Analysis of lethality rescuing VD1 mutants with talin H50 
As seen in the interaction between TarP VBSs with VD1, the binding of a VBS to VD1 
may follow a certain consensus of residues in order to bind effectively, but with small 
variations in sequence and structure of the VD1-VBS interface region having drastic 
effects on binding affinity. The Vinculin lethality supressing mutants (discovered through 
a genetic screen, unpublished data) A50I, P15L and W253X showed that small 
mutations can result in reduced binding affinities, although the W253X mutant exhibited 
Kd values consistent with the WT while somehow rescuing the Drosophila from lethality 
.These mutants can disrupt talin VBS-VD1 binding and as such rescue Drosophila from 
lethality caused by CO vinculin. This disruption of talin VBS-VD1 binding was mostly 
consistent across tested talin VBS (helixes 6,27,33,36 and 50) (Data generated by Dr 
Karen baker Postdoc Goult lab), however H50 exhibited only mild increases in Kd and 
was the only helix tested to actively bind all three of the mutants including the A50I 
mutant which was reported to disrupt the talin: vinculin interaction. Crystal structures of 
each VD1 mutant with H50 would allow direct analysis as to how and why H50 allows 
the binding of these VD1 mutants. While numerous attempts were made as seen in 
section 2.5.8 to acquire crystals for each complex only the W253X-H50 complex 
successfully diffracted and as such the only structure available for direct analysis of any 
unique binding interactions or structural changes.  
3.2.1 VD1 mutant W253X with talin helix 50 structure 
The W253X-H50 was determined at a resolution of 2.11Å in an P21 monoclinic space 
group with one molecule of the complex in the Au with a probability of 100% using 
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Matthews coefficient. Pisa analysis shows that 48.5% of the H50 peptide is buried  in 
the complex interface, further details of validation and quality analysis can be seen in 
figure 23. VD1 residues 1-3, 34-35 and 221-225 are missing as well as H50 residues 
2075-2078 and 2100-2103, these residues are all present in disordered loop regions. 
The same helical bundling insertion is seen with hydrophobic interactions inside the 
Figure 24-(Top) Structural statistics of the W253X (blue) -H50 (orange) crystal structure as 
determined in CCP4i2 REFMAC program. (Bottom) TarP W253X-H50 structure modelled in PyMOL 
showing the helical insertion of the H50 peptide between helices α1 and α2 of VD1. Interface residues 




Figure 24-(Top) Structural statistics of the W253X (blue) -H50 (orange) crystal structure as 
determined in CCP4i2 REFMAC program. (Bottom) TarP W253X-H50 structure modelled in PyMOL 
showing the helical insertion of the H50 peptide between helic  1 and 2 of VD1. Interface residues 


























core of the N-terminal helical bundle of the W253X mutant. Comparing the W253X-H50 
with the WT-H50 (PDB 4DJ9,(Yogesha et al., 2012), the semi-conserved hydrogen 
bond between VD1 glutamine 19 and serine 2096 as seen in both TarP VBS1 
(Whitewood et al., 2018) and 3 is present but not in wildtype VD1 with H50 as seen in 
section 3.1.5. Although both the W253X and WT complexes share a hydrogen bond in 
between VD1 Q19 and G2092 (figure 24C). The hydrogen bond mention from W253X 
Q19 to H50 S2096 is not seen in the WT, however this hydrogen bond can be formed in 
the WT structure simply by altering the S2096 into a different but still acceptable 
rotamer. Possibly the WT VD1 may favour the serine in a non-hydrogen bonding 
rotamer while the W253X favours a hydrogen bonding serine rotamer. 
The W253X-H50 and WT-H50 structures overlaid reveal that all the residues appear to 
conserve their positions apart from the hydrogen bond mentioned and one other minor 
difference. In the WT-H50 structure a lysine in the H50 Peptide K2099 is pointed 
towards a positively charged Histidine H27 in the α1 helix of VD1. In the W253X-H50 
structure this lysine is pointed away from the α1 helix and the W253X H50 interface 
region, this difference may be the reason why the α1 helix in W253X appears to shift 
slightly towards the H50 peptide (figure 24 A, B). The six C-terminal residues removed 
in the W253X mutant are in a unstructured loop region that interconnect the region 
between VD1 and VD2, their deletion appears not to intrinsically interfere with the 
binding of the H50 peptide to the W253X mutant when compared the WT interaction. 
These small structural differences between the two structures do not answer the 





Figure 25-(A) The W253X-H50 (blue, orange) 
structure overlaid on the WT VD1-H50 (green, 
pink) structure with Interface residues side 
chains are modelled using the 
interfaceresidues.py script in PyMOL. 
(B) K2099 reorientates in the W253X-H50 
complex to face away from the positively 
charged H27, compared to the WT VD1-H50 
where it faces towards the VD1 helix 1. 
(C) The W253X-H50 structure shows VD1 Q19 
able to hydrogen bond to both S2096 and 
G2092, whereas the WT VD1-H50 is only able 
to hydrogen bond to G2092. 
 
 
Figure 25-(A) The W253X(blue)-H50(orange) 
structure overlaid on the WT VD1(green)-
H50(pink) structure with Interface residues side 





























































































































3.3. Project 3:α-catulin structural characterisation and its homology to Vinculin 
Biochemical/biophysical techniques were performed to identify any structural similarities 
between vinculin and α-catulin, as well as explore whether binding interactions seen in 
vinculin are also present in α-catulin. Also utilising bioinformatic techniques to analyse 
sequence similarities between vinculin and α-catulin. 
3.3.1 Cloning α-catulin constructs into new vectors 
The N-terminal ACH (1-283) did not express from the pET151 N-terminal His-tag vector 
and attempts to clone the ACH into both a C-terminal HIS-Tag vector (pET 21a) and a 
pGEX GST vector, were both unsuccessful. Attempts to clone α-catulin full length (1-
731), α-catulin ‘VD1-3’ (1-529), α-catulin ‘VD3’ (307-529) and α-catulin ‘VBS domain’ 
(284-615) into a pET151-avi-2I27-mR6-2I27-spy vector also proved unsuccessful. 
However, the C-terminal ACT (533-731) expressed and purified well and was used in 
the following assays. 
3.3.2 NMR spectra of the ACT 
The predicted high structural similarity between VT and ACT region meant that potential 
binding interactions seen in VT may also bind to ACT. Paxillin’s LD2 domain has been 
shown to bind both VD1 and VT (albeit weakly) (Wood et al., 1994), so we used 2D 
NMR to identify if this was observed for the ACT.  
1H 1D and  1H -15N 2D transverse relaxation optimised spectroscopy (TROSY) NMR 
spectra were performed on the ACT to acquire a fingerprint spectrum. Both spectra 
were run with the same 50 µM 15N labelled ACT sample loaded at 350 µl into Shigemi 
NMR tubes with 5% D2O.  
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The 1D spectra indicates the presence of protein with peaks present in the 
amide/backbone region (6-10 ppm) but the peaks are broad indicating that protein 
concentration appears to be insufficient or forming a higher order species (aggregated). 
Normally a concentration of 100 µM-1 mM is required for a clear signal and higher 
defined peaks. This together with the lack distinct methyl group peaks (0-1.5 ppm), 
which in a higher concentration may indicate the protein is unfolded but, in this case it 
was more likely the concentration was simply not high enough for clear definition. The 
TROSY experiments showed poorly defined peaks owing most likely to low 50 µm 
concentration mirroring what was shown in the 1D experiment. The poorly defined 
peaks in the spectra however indicated a possibility that the ACT was behaving like a 
protein of a higher MW, as MW increases definition decreases and the peaks become 
broader. The ACT sample showed no clear sign of aggregation, but it was possible that 
it was forming a dimer (possibly confirmed in gel filtration see below) or aggregating and 
as such the spectra given was one of a much larger protein and as such much less 
defined. (Note the His-tag was not cleaved due to concern the small concentration 
might be lost through the addition of TEV).This lack of definition of the peaks meant 
subsequent experiments with peptides such as the paxillin LD2 could not be performed 
as shifts seen in VT and Paxillin are extremely subtle and as such in the ACT would not 
be seen. While the spectra gave a fingerprint of the ACT, the poor definition precludes 
further experiments and requires further optimisation. The concentration used could be 
on reason while the spectra is highly defined, but also the ACT forming aggregates 




Figure 26-(Top) A 1D NMR spectra of the ACT show the presence of protein from peaks in the amide 
regions (chemical shifts 6-10 ppm). (Bottom) 2D TROSY spectra of the ACT, the TROSY data peaks 
are not well defined due to the low 50 µM concentration. NMR spectra performed with one biological 
replicate.  
 
Figure 26- (Top) A 1D NMR spectra of the ACT in both which show protein presence from peaks in 
the amide regions (chemical shifts 6-10ppm). (Bottom) 2D TROSY spectra of the ACT, the TROSY 
data peaks are not well defined due to the low 50 µM concentration. 
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finding conditions in which aggregation may not occur would, alongside cleaving the 
His-tag would all aid in refining the spectra. 
3.3.3 CD comparison between ACT and VT  
The secondary structure of the ACT was analysed using Far UV as well as using a 
melting curve to determine the overall thermal stability of the protein. This was run 
alongside the VTΔlinker for a direct comparison. The Far UV spectrum of the ACT was 
run at 4.4 µM in 1x PBS indicates an alpha helical structural as shown by the prominent 
‘double dip’ trace seen between wavelengths ~208 and ~227. 
The spectra for the VTΔlinker mirrors that of the ACT with the double dip present also 
indicating an alpha helical structure (figure 26A). The melting curve for the ACT run at 
20-90°C shows high levels of thermal stability with a melting temperature (TM) of 
~85°C, although no real change occurs until ~90°C whereupon its folded structure 
appears to be truly disrupted. The spectra of the VTΔlinker again mirrors the ACT with 
both sharing the same~85°C TM and the full disruption of the folded structure at ~90°C 
(figure 27B). While the VT has been clearly shown to be a 5 helix bundle as seen in 
crystal structures (PDB 1QKR, (Bakolitsa et al., 1999), the ACT has only been predicted 
through online structural programs that predict secondary structure based on protein 
homology databases such as Phyre2 and T-Coffee MSA. All spectra were blanked 
























































Figure 27-A) Far UV comparison between the ACT and VT indicating both share a largely α-helical 
secondary structure as visualised by the characteristic double dip shape of the spectra. B)The melting 
curve spectra shows that both the ACT and VT share high stability, unfolding occurring at ~85°C for 
both. Both far UV and melting curve CD assays performed with 3 biological replicates. 
 
Figure 27-A) Far UV comparison between the ACT and VT indicating both share a largely α-helical 
secondary structure as visualised by the characteristic double dip shape of the spectra. B)The melting 




















































































3.3.4 Analysis of ACT association with VD1 using gel filtration 
The structural homology between the ACT and the VT suggests that the ACT may 
associate with VD1, as VT binds to VD1 in its autoinhibited state. Perhaps ACT may 
bind to VD1 and indicate a mechanism for a possible vinculin-α-catulin complex. Gel 
filtration SEC was carried out to determine whether ACT (22 kDa) associated with VD1 
(29 kDa). Each protein eluted at separate retention volumes with the larger peaks of  
both VD1 and ACT eluting at 15 ml and 16 ml, respectively. Both also showed 
secondary peaks at 13 ml for VD1 and 14 ml for ACT which could indicate dimerisation 
for VD1 and possible dimerization for the ACT, possibly indicating another similarity 
between the two. The ACT:VD1 mix appears to show no new peaks when compared to 
the Apo proteins, although the peaks for the Apo proteins appear lower this is likely due 
to concentration fluctuations in the sample due to loss of sample volume while loading. 
The somewhat similar MW of both VD1 and ACT mean that substantial overlap occurs 
around 14-16 ml however all peaks for both VD1 and ACT remain at the same retention 
volume albeit with higher UV values. If an association of VD1 and ACT had occurred a 
new peak would be present between the VD1 dimer peak at 13 ml and the ACT 
possible dimer at 14.5 ml, which is not seen. While this gives some indication that there 
is no association between VD1 and the ACT, overall, with concentrations not being 
equal between the apo and mix samples I would say this interaction so far is 
inconclusive. Also, no control run was performed which would have been VD1 with the 
VT, which would have also defined if the VD1 was properly folded etc that would have 
then shown a negative association across all runs including the ACT run as seen. 
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3.3.5 FP of the ACT with Paxillin LD2  
The VT has been shown to interact weakly with paxillin’s LD2 domain, as ACT shares 
homology with the VT an FP assay was performed to identify whether this interaction 
with LD2 might also occur for α-catulin. Paxillin’s LD2 domain has been shown to be 
important in the recruitment of both vinculin and talin to FACs (Pasapera et al., 2010), 
an interaction between paxillin’s LD2 and α-catulin could indicate that possibly α-catulin 
is also recruited to FACs or perhaps that paxillin is then associated with the DAPC. 
While the FP assay shows that ACT has a very similar binding curve as VTΔlinker the 
Kd was unable to be determined much the same as the FP assay between VTΔlinker 
and LD2. As mentioned in section 3.3.2 a TROSY NMR experiment with the ACT and 
Figure 28-Gel filtration SEC data indicating the lack of association between the ACT and VD1 
domain. Each sample was run 56 µm, although fluctuations in sample volume with the variation in 
peak height in both ACT and VD1 apo runs is present. GF SEC assay performed with 2 biological 
replicates. 
 
Figure 28- Gel filtration SEC data indicating the lack of association between the ACT and VD1 
domain. Each sample was run 56 µm, although fluctuations in sample volume with the variation in 





















paxillin LD2 would have helped to confirm this interaction but as mentioned was not 
possible. While this interaction could indicate that ACT could possibly interact with 
paxillin through the LD2 domain the interaction is very weak and could possibly just be 
non-specific binding due to high concentrations of each protein used in the FP assay.  
If 
the 
ACT were optimised for NMR an interaction with LD2 could be proved this would help to 
corroborate the FP data shown (figure 29). This alongside expressing constructs of full 
length or multidomain parts of α-catulin, may also help to prove that perhaps paxillin’s 
interaction with the α-catulin may not be exclusive to the ACT. Paxillin may bind α-
Figure 29-FP shows that the ACT binds weakly to paxillin’s LD2 domain much like the VT, the VT has 
been shown to bind to paxillin’s LD2 domain and even though the Kd cannot be determined for either 
in this study it suggest an interaction between the ACT and paxillin is possible. FP was performed with 
two biological replicates. 
 
Figure 29-FP shows that the ACT binds weakly to paxillin’s LD2 domain much like the VT, the VT has 
been shown to bind to paxillin’s LD2 domain and even though the Kd cannot be determined for either 
in this study it suggest an interaction between the ACT and paxillin is possible. 
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catulin across multiple domains, the apparent weak binding seen between the ACT and 
the LD2 domain may only be one part of a stronger interaction between paxillin and α-







4 Discussion  
4.1. Project 1:TarP vinculin binding site structure and stoichiometry 
Vinculins ability to recruit and bundle actin to FACs (Wen et al., 2009) as well as 
cadherin cell-cell junctions (Leerberg and Yap, 2013) plays a key part in cellular 
migration as well as cellular homeostasis. This has led to bacterial pathogens obtaining 
virulence factor proteins that contain VBS motifs that hijack vinculin to facilitate their 
entry into host cells. Bacteria such as Rickettsia which uses a cell surface antigen Sca4, 
Shigella with its IpaA invasion protein and Chlamydia with its T3SS protein TarP. Each 
virulence protein being able to recruit vinculin though VBS-VD1 interactions and 
repurpose vinculin for their pathogenesis cycle. 
This study attempted to examine the specific binding interactions between the three 
VBS present in C.caviae TarP and vinculin. Biochemical and biophysical techniques 
were used to determine these binding affinities and structural interactions between the 
three VBS and VD1 alongside determining the stoichiometry of VD1 bound to the 
C.caviae TarP three VBSs concurrently.  
4.1.1 A structural Comparison between the three TarP VBS bound to VD1  
C.caviae TarP VBS1 had previously been shown to bind to VD1 using the same helical 
bundling method as seen with talin VBSs and had actively outcompeted talin in binding 
to VD1 with Tarp VBS1-VD1 showing a high Kd value of 1290 nM, (Whitewood et al., 
2018). By using an FP assay, we have been able to determine the Kd for the TarP VBS3 
and determined that its binds to VD1 with a higher binding affinity than TarP VBS1. By 
testing both TarP VBS1 and VBS3 it is shown that TarP VBS1 binds with an affinity of 
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223 nM whereas TarP VBS3 binds with an affinity of 81 nM. A hypothesis on what 
causes the difference in binding affinity between the two VBS can be made by 
comparing the previously solved TarP VBS1-VD1 structure (6FQ4,(Whitewood et al., 
2018) and the TarP VBS3-VD1 structure solved here.  
In section 3.1.5 the structure of the TarP VBS3-VD1 shows that TarP VBS3 binds VD1 
in much of the same way that TarP VBS1 does with interactions between a lane of 
hydrophobic residues in TarP VBS3 with the hydrophobic core of the N-terminal helical 
bundle of VD1. A difference in hydrophobic residues is seen between TarP VBS1 and 
TarP VBS3 however, TarP VBS1 as has two polar residues T857 and T864 in contact 
with the VD1 hydrophobic core whereas TarP VBS3 has a L753 and V760 at the same 
positions. This inclusion of a L753 and V760 TarP VBS3 results in it having two extra 
hydrophobic residues that can interact with the hydrophobic core of VD1 and as such 
could be the reason for the enhanced binding affinity shown by the FP data of the TarP 
VBS1 compared to 3. 
While the affinity of TarP VBS2 could not be determined due to solubility issues with the 
peptide, using PyMOL the residues of the TarP VBS3 peptide were mutated to the TarP 
VBS2 sequence and a prediction can be made onto its affinity using the consensus 
sequence alongside the model (figure 29, 30). The TarP VBS2 sequence shows high 
homology with the consensus sequence with two small deviations, TarP VBS2 has 
Figure 30-MSA of the conserved VBS residues in talin as well as bacterial virulence factors TarP,Sca4 
and IpaA. Redrawn with Clustal Omega using sequences from Whitewood et al., 2018. 
 
Figure 30-Multiple sequence alignment of the conserved residues across talin VBS as well as the 
bacterial virulence factors TarP,Sca4 and IpaA VBS’s. Adapted from Whitewood et al., 2018. 
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Figure 31-A) Conserved hydrophobic residues for the TarP VBS1, B) TarP VBS2 and C) TarP VBS3. 
D) Overlay of all the conserved residues between all three of TarP’s three VBSs. Note TarP VBS1 is 
missing its L850 from the structure and as such is not modelled, which would overlay with TarP VBS2 
I806 and TarP VBS3 L746. 
 
Figure 31-A) Conserved hydrophobic residues for the TarP VBS1,B) TarP VBS2 and C) TarP VBS3. D) 
Overlay of all the conserved residues between all three of TarP’s three VBS. Note TarP VBS1 is 
missing its L850 from the structure and as such is not modelled, which would overlay with TarP VBS2 






























































































































































an alanine A821 in place of a Leucine found in both TarP VBS1 and 3 and while alanine 
is hydrophobic its reduced capacity for hydrophobic interactions may cause some 
reduction in affinity. Additionally, it has an alanine A826 in place of the conserved 
Arginine/lysine, while a hydrogen bond was seen in the TarP VBS1 involving the 
arginine it was not seen in other VBS-VD1 complexes and deemed not important in 
binding although conserved. These slight differences might imply that TarP VBS2 may 
bind weaker than TarP VBS3 but stronger that TarP VBS1 which as mentioned is 
lacking two key hydrophobic residues. Indicating that perhaps C.caviae TarP VBSs 
have a VBS3>VBS2>VBS1 hierarchy in terms of affinity for vinculin. 
When looking at sequence consensus between the three TarP VBS it appears that 
VBS1 and 2 share portions of homology in residues that appear not in the consensus 
sequence, VBS1 N856 and VBS2 N812 are shared alongside VBS1 T859 and VBS2 
T814 and VBS1 K867 and VBS2 K823. All three of these are not seen in VBS3. While 
perhaps not immediately apparent this does give rise to the theory that VBS1 is the 
original VBS in TarP and through duplication mutations occur in VBS2 and again until 
reaching VBS3 which then shows the highest affinity so far. This works in tandem with 
as shown above VBS1 has fewer key hydrophobic residues in the core interface region 
and this amount increases in VBS2 until VBS3 where key hydrophobic residues appear 
to give the highest affinity. This indicates that perhaps TarP VBS1 was the original TarP 
VBS and through duplication mutations, each subsequent VBS increases in number of 
key hydrophobic residues and subsequently an increase in affinity for vinculin. This 
increase in affinity could have enhanced TarP’s ability to form complexes needed for the 
internalisation of the EB. 
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4.1.2 The stoichiometry of Vinculin binding to TarP VBS1-3 
The binding data for TarP VBS3 proved that multiple high affinity VBS are present in 
C.caviae TarP C-terminal, but as all of the TarP VBS are present in close proximity to 
each other the question arose of how many VBS could be bound to vinculin at one time. 
By performing a GST pulldown, we found that TarP VBS1-3 GST could associate with 
VD1 in a 1:3 ratio (figure 19), indicating that each VBS can bind one VD1 monomer 
concurrently. While the GST pulldown did show some traces of VD1 in the supernatant 
the vast majority of the VD1 associated with the TarP VBS1-3 GST attached to the 
glutathione beads in the pellet. While this result shows a good confirmation that the 
stoichiometry of TarP VBS1-3 GST to VD1 ratio is 1:3 the SEC-MALS assay would 
have proved this ratio by measuring the MW accurately to see if three VD1 monomers 
do truly associate with the TarP VBS1-3 GST-tagged. The SEC-MALS however were 
unsuccessful due to reasons explained in section 3.1.4 and would need to be repeated 
to corroborate the GST-pulldown data.  
The size of the regions separating the three TarP VBS at the C-terminal region of TarP 
is something that could possibly influence the predicted 1:3 ratio of TarP VBS1-3 to 
VD1, if the regions between each VBS are too short for example this could physically 
inhibit the binding of multiple vinculin. While no structure of the entire TarP VBS1-3 
region exists, a structural model was made using residues 745-868 with the linker 
regions between each TarP VBS added. Note the linker region between TarP VBS3 and 
2 is a ~44aa disordered loop, while the TarP VBS2 has an additional short helical region 
after the consensus VBS and a short ~6 aa disordered loop region connecting it to TarP 
VBS1. The secondary structure prediction software PSIPRED was used to determine 
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these linkers (figure 31). Viewing the model, it seems possible that all three TarP VBS 
can bind a VD1 monomer, although the linker region between TarP VBS2 to VBS1 is 
only 6 residues it appears that the VD1 monomers are able to bind each TarP without 
being physically blocked. Additionally, although not modelled the remaining residues in 
the TarP protein are primarily disordered and as such may not appear to interfere as 
much with the VBS region in comparison to fully formed helical or β-sheet domains. 
While the model suggests that three VD1 monomers can bind concurrently to TarP 
VBS1-3, in vivo the TarP will be binding to full length vinculin not just VD1. The 
difference between TarP VBS1-3 binding to three VD1 monomers and binding to three 
Figure 32-(Top) PyMOL model of TarP VBS1-3 (745-868) with three VD1 molecules to indicate in the 
linkers physically allow this 1:3 binding stoichiometry. TarP VBS1 red, TarP VBS2 pink, TarP VBS3 
orange with the linkers in yellow. (Bottom) PSIPRED secondary structure analysis of TarP VBS1-3 
residues 745-868 showing each TarP VBS (pink) and the two linker regions between them. 
 
Figure 32-(Top) PyMOL model of TarP VBS1-3 (745-868) with three VD1 molecules to indicate in the 
linkers physically allow this 1:3 binding stoichiometry. TarP VBS1 red, TarP VBS2 pink, TarP VBS3 
orange with the linkers in yellow. (Bottom) PSIPRED secondary structure analysis of TarP VBS1-3 
residues 745-868 showing each TarP VBS (pink) and the two linker regions between them. 
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full length vinculin monomers, in terms of the physical spacing between protein chains 
will certainly be substantially different.  
4.1.3 Does TarP VBS stoichiometry change throughout the chlamydial 
pathogenesis cycle? 
In a recent study by Pedrosa et al they suggest that TarP has a post invasion role after 
the internalisation of the Chlamydial EB (Pedrosa et al., 2020). This post-invasion role 
for TarP see it modulating the dynamics and organization of host cell focal adhesions 
This post invasion role envisions TarP molecules being inserted into FACs and actively 
reorganising and stabilising them, this results in more FACs being formed and reducing 
he motility of the infected cells through higher numbers of cell-ECM contacts. This 
higher number of cell-ECM contacts appears to suggest that higher contact between the 
cell and the ECM will reduce apoptotic signals associated with cell detachment (Frisch 
and Francis, 1994; Gudipaty et al., 2018).This post invasion role differs considerably 
from the actin recruiting and remodelling for EB internalisation seen early in invasion 
and expands a theory that each VBS present in TarP may be used at differing times 
throughout the chlamydial pathogenesis cycle, as both the roles that TarP exhibits rely 
on the TarP VBS domains interaction with vinculin. So perhaps in initial invasion a 
certain TarP VBS or number of VBSs are needed to facilitate invasion while in the post 
invasion role a different configuration of VBS interactions may be required. Previously a 
study by Thwaites et al. suggested that the TarP VBS1 in C.caviae was essential in the 
initial invasion stage where it bound and recruited vinculin, with both TarP VBS2 and 3 
being deemed dispensable (Thwaites et al., 2015). In the study Thwaites mentions 
however that if investigated TarP VBS2 and 3 may appear to have roles in stabilisation 
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and maturation of the protein complex although no data is presented for this. The data 
collected throughout this study may help to corroborate the link between Pedrosa’s post 
invasions role for TarP and Thwaites study of TarP VBS1 being essential for invasion. 
Possibly during initial invasion, the C-terminal TarP VBS1 is all that is required to bind 
and recruit Vinculin for invasion while TarP VBS 2 and 3 are dispensable. However, 
when the TarP is then integrated into FACs post invasion all three VBS might be utilised 
to bind multiple vinculin molecules rearranging and stabilising FACs connection to the 
ECM. The higher binding affinity seen in TarP VBS3 to VD1 may also indicate that its 
role is required more in stabilisation rather than the recruitment role seen in TarP VBS1 
which exhibits a slightly lower binding affinity to VD1. While speculation the data 
collected in this study possibly supports the idea that there could be varying 
configurations of TarP VBS bound to vinculin throughout different stages of the 











4.2 Project 2: Lethality rescuing VD1 mutants’ unique interactions with talin H50 
This study aimed to analyse the binding interactions between the three A501, P15L and 
W253X with the VD1 mutants and talin H50, binding interactions proved by FP (Data 
generated by Dr Karen Baker Postdoc Goult lab) showed high levels of disruption in 
VBS and mutant VD1 binding in the tested VBS. This disruption of talin vinculin 
interactions in Drosophila lead to the rescue from lethality when hyper-active CO 
vinculin was introduced. While disruption seemed mostly uniform across the VBS, H50 
in talin showed considerably less disruption in binding with the VD1 mutants. Uniquely 
H50 was able to bind the A50I mutant with a Kd of 1.015 µM, whereas in other talin VBS 
the binding was disrupted giving affinity values between Kd 14 µM and 38 µM.  
In this study the W253X-H50 structure was solved and the binding interactions analysed 
to determine why the W253X deletions of the last six residues of VD1 can rescue the 
Drosophila lethality phenotype. 
4.2.1 The structural comparison between the W253X-H50 and the WT VD1-H50 
structures indicates subtle differences in interactions and helix placement  
In section 3.2.1 the W253X-H50 was compared to the WT VD1-H50 structure (4DJ9) 
the two complexes overlaid appeared structurally conserved apart from an additional 
hydrogen bond VD1 Q19 to H50 S2096 and the position of H50 lysine K2099. In 
W253X-H50 K2099 is orientated away from the binding interface whereas in the WT 
VD1-H50 its orientated spatially towards a histidine in the VD1 α1 helix, one positively 
charged residue repulsing another and causing a slight shift in WT VD1 α1 helix. This 
displacement of α1 helix  in VD1 is by this lysine residue as mentioned in WT VD1-H50 
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study (Yogesha et al., 2012) however they attribute a different histidine (H22) that could 
be repulsing the lysine residue, however H27 positions seems more indicative of 
interacting with K2099 and displacing the α1 helix of VD1, however is most likely a 
combination of the two. This results in the WT VD1 α1 helix being shifted away from the 
H50 peptide by a small degree, in the W253X-H50 structure this shift is still present but 
to a lesser degree suggesting the lysine’s position is not solely responsible for this helix 
shift but plays a large role.  
This change of K2099 orientation is only seen in W253X-H50 complex and the deletion 
of the last six residues somehow causes this change, a theory to why this occurs could 
be that an interaction/spatial restraint between the last six residues in α7 and the first 5 
in α1 of VD1 may cause this slight shift in the α1 helix. This interaction is not completely 
modelled in either H50 structure, but can be seen in the Shigella IpaA-VBS3 in complex 
with human VD1 structure (PDB 3RF3 (Watabe-Uchida et al., 1998). Note that both the 
last six residues and the first five residues are disordered loops. The presence of the 
Figure 33-PyMOL model of residues 1-5 (yellow) region of VD1 in contact with residues 253-258 
(red) of VD1 both present in disordered loops. PDB 3RF3 Watabe-Uchida et al., 1998. 
 
Figure 33-PyMOL model of residues 1-5 (yellow) region of VD1 in contact with residues 253-258(red) 









last six residues of VD1 could possibly constrain the first five residues of VD1 to a small 
degree, this constraint leads to a VD1 phenylalanine F4 to interact with three 
hydrophobic residues I9, L13 and A17 in the VD1 α1 helix, maintaining the α1 helix at 
an angle. This interaction in combination with the K2099 repulsion of the histidine H22 
could maintain α1 in its shifted position away from the H50 peptide in the WT VD1-H50 
complex. In the W253X-H50 complex the last six residues are deleted and the F4 
interactions with I9, L13 and A17 are disrupted. This alteration could possibly cause the 
α1 helix to shift back towards the H50 peptide and in the process the repulsion from the 




















































































orientation away from the binding interface altogether. Unfortunately, the last six and 
first five residues are in disordered loops and not fully modelled in either the W253X or 
WT VD1 models and the theory of their interaction and thus lack of it causing this shift in 
the α1 helix, is at the moment conjecture based on several different. VD1-VBS 
complexes and further data is required to make a more conclusive analysis. The lysine 
orientation, additional hydrogen bond and α1 helix shift towards the H50 however do 
result in a slight difference in binding affinity between the WT VD1-H50 and W253X-H50 
with each showing Kd values of 610 nM and 515 nM respectively (figure 34). Indicating 
that the deletion of the last six residues in W253X mutant does have small effects on 
the binding affinity.  
 
Figure 34-A) In the WT VD1-H50 (green, pink) structure F4 appears to be close enough to establish 
hydrophobic interactions with I9,L13 and A17 keeping the α1 helix in its shifted conformation away 
from H50. B) In the W253X-H50 (blue, orange) structure F4 appears to favour a different rotamer and 
appears not to interact with I9, L13 and A17 as closely which could possibly cause the shift in the α1 
helix of VD1 to shift towards the H50 peptide. C) Overview of the F4 interactions linked with the shift in 
the α1 helix one of VD1 and the displacement of K2099 in the W253X-H50 structure, perhaps through 
repulsive interactions from H22 and H27 caused by the shift in the α1 helix. 
 
Figure 34-A) In the WT VD1 (green)-H50 (pink) structure F4 appears to be close enough to establish 
hydrophobic interactions with I9,L13 and A17 keeping the α1 helix in its shifted conformation away 
from H50.B) In the W253X (blue)-H50 (orange) structure F4 appears to favour a different rotamer and 
appears not to inter ct with I9, L13 and A17 as closely which could possibly cause the shift in the α1 
helix of VD1 to shift towards the H50 peptide. C) Overview of the F4 interactions linked with the shift in 
the α1 helix one of VD1 and the displacement of K2099 in the W253X-H50 structure, perhaps through 
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Figure 35-FP data of lethality rescuing VD1 mutants being tested against talin helixes 6, 27, 33, 36 
and 50.The VD1 mutants are A50V, W253X, P15L, A50I and double mutants P15LA50V, 
P15LW253X and A50VW253X. (Data generated by Dr Karen Baker Postdoc Goult lab). 
 
Figure 35-FP data of lethality rescuing mutant VD1’s being tested against talin helixes 6, 27, 33, 36 
and 50.The VD1 mutants are A50V, W253X, P15L, A50I and double mutants P15LA50V, 
P15LW253X and A50VW253X. (Data generated by Dr Karen Baker Postdoc Goult lab). 
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4.2.2 What causes the W253X mutant to rescue Drosophila from lethality 
Why the W253X mutant results in rescuing Drosophila from lethality is something that 
from the structure or biochemical analyses is not apparent, as the deletion of the last 6 
residues is all that differs from the WT VD1. These residues could  possibly interact with 
other proteins to cause this phenotype, as from the structure they do not negatively 
interact with VBS binding, when compared to the A50I and P15L mutants. Figure 34 
shows that the deletion of these residues only strengthens the binding affinity, this 
strengthening of binding affinity caused by the W253X mutant is not unique to H50 as 
all the tested talin VBS shared this increase in binding affinity. Additionally, double 
mutants of P15LW253X show large increases in affinity compared to the single P15L 
mutant.  
One possibility is that the last six residues may be important in forming VD1:talin 
aggregates, although these aggregates have been shown not to be essential for the 
lethality phenotype their involvement has not been ruled out (Maartens et al., 2016). 
VD1 it is known to dimerise after time in vitro, perhaps VD1 dimerisation plays a role in 
aggregate formation and by deleting the last six residues this is disrupted and the 
Drosophila are rescued from lethality phenotype. This is just a possibility and until more 
structures of these VD1 mutants in complex with H50, especially double mutants like 
the P15LW253X, why the W253X mutant rescue Drosophila will remain conjecture.  
4.2.3 How is the H50 able to bind to both the A501 and P15L VD1 mutants 
Both the A50I and P15L (figure 35) mutations caused complete disruption in binding in 
the majority of talin VBSs tested, an outlier was seen when binding to H50 Kd values 
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where A50I bound with 1015 nM and P15L with 1258 nM. This points to a unique 
interaction between H50 and both A50I and P15L. While the A50I-H50 and P15L-H50 
structures aren’t available, by comparing the WT VD1-H50 to another VD1-talin VBS 
structure for example the VD1-talin helix 33 (H33) structure (PDB 3S90,(Yogesha et al., 
2011) we may identify why H50 binds to both these VD1 mutants. 
When the WT VD1-H50 structure is compared to WT VD1-H33 structure, some 
similarities and differences are seen. Both share the lysine interacting with the α1 helix 
Figure 36-(Top) PyMOL model depicting the A50I VD1 mutation, the larger hydrophobic isoleucine 
causing possibly limiting a VBS interaction with the VD1 hydrophobic core.(Bottom) PyMOL model 
depicting the P15L mutation that would cause an alteration in the α1 helix of VD1 again possibly 
restricting a talin VBS from binding. PDB 4DJ9,Yogesha et al.,2012.PDB 3S90,Yogesha et al., 2011. 
 
Figure 36-(Top) PyMOL model depicting the A50I VD1 mutation, the larger hydrophobic isoleucine 
causing possibly limiting a VBS interaction with the VD1 hydrophobic core.(Bottom) PyMOL model 
depicting the P15L mutation that would cause an alteration in the α1 helix of VD1 again possibly 
restricting a talin VBS from binding. PDB 4DJ9,Yogesha et al.,2012.PDB 3S90,Yogesha et al., 2011. 
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Histidine, however H33’s K1544 seems not to be able to interact with Histidine 27 as is 
seen in the H50 structure. The H33 structure VD1 α1 helix is shifted away from the H33 
peptide but not to the same degree as the H50 structure (figure 36). A sequence 
alignment shows that both H50 and H33 share residue conservation broadly especially 
with the hydrophobic residues, but some differences are seen between residues 
towards the C-terminus of the VBS (figure 37). The H50 VBS has three key residue 
differences in this region compared to H33, in H33 the residues A1537, K1541 and 
T1542 and in H50 these are all substituted with residues with smaller sidechains 
G2092, S2096 and A2097, respectively. 
Additionally, the VD1-H50 and VD1-H33 complexes differ in the number of interactions 
between the VD1 and VBS, VD1-H50 has only one hydrogen bond whereas the VD1-
H33 complex has five hydrogen bonds as well as a salt bridge. The difference in 
Figure 37-A structural comparison between the WT VD1-H50 (green, pink) structure and the WT VD1 -
H33 (red, cyan) structure shows the conserved lysine is positioned differently, in the H50 structure 
K2099 appears to be orientated more towards both H22 and 27 in α1 helix of VD1 and as such the α1 
helix is positioned further away from the H50 peptide. In the H33 structure K1544 appears to be 
orientated in a position where H27 has a weaker interaction and as such K1544 seems to orientate 
solely by the position of Histidine 22, this allows VD1 helix one to be able to associate more closely with 
H33 than in the H50 structure. PDB 3S90,(Yogesha et al., 2011) 
 
Figure 37-A structural comparison between the WT VD1 (green)-H50 (pink) structure and the WT VD1 
(red)-H33 (cyan) structure shows the conserved lysine is positioned differently, in the H50 structure 
K2099 appears to be orientated more towards both H22 and 27 in α1 helix of VD1 and as such the α1 
helix is positioned further away from the H50 peptide. In the H33 structure K1544 appears to be 
orientated in a position where H27 has a weaker interaction and as such K1544 seems to orientate 
solely by the position of Histidine 22, this allows VD1 helix one to be able to associate more closely with 






residues size and the lack of constraint caused by polar/electrostatic interactions may 
mean that the H50 is able to accommodate the A50I and P15L mutants.  
The ability of the P15LW253X (376 nM) double mutant to bind with a higher affinity 
when compared to the single P15L (1258 nM) mutant also shows how the α1 helix shift 
seen in the W253X-H50 complex may occur, with the W253X mutation creating another 
level of accommodation for mutations.  
  
Figure 38-MSA using Clustal Omega of talin helices containing VBSs, H50 appears to have 
residues with smaller sidechains (yellow) which may aid in its ability to accommodate the VD1 
mutants such as A50I and P15L. 
 
Figure 38- Multiple sequence alignment using Clustal Omega of talin helices containing VBS’s, H50 
appears to have residues with smaller sidechains (yellow) which may aid in its ability to 
accommodate the VD1 mutants such as A50I and P15L. 
Talin_H4|607-636         ------------PLLQAAKGLAGAVSELLRSAQPASAEPRQN-30 
Talin_H33|1512-1546      ASARTANPTAKRQFVQSAKEVANSTANLVKTIKA-------- 34 
Talin_H36|1628-1652      --------PRWSVLAGHSRTVSDSIKKLITSMR--------- 25 
Talin_H50|2078-2099      -----------VVLINAVKDVAKALGDLISATK--------- 22 
                                      :    : :: :  .*: : :          
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4.3 Project 3:α-catulin structural characterisation and comparison to Vinculin 
The structural homology of α-catulin to vinculin and α-catenin indicated that possibly α-
catulin could possibly engage in some of the same binding interactions seen in Vinculin 
but are also shared in α-catenin.  
Through an FP assay an interaction between the ACT and paxillin’s LD2 domain was 
seen although the Kd could not be determined as the interaction is weak, though GF an 
interaction between the ACT and VD1 was not seen so remains inconclusive. 
4.3.1 The ACT binds weakly to Paxillin’s LD2 motif much like the VT  
The VT was shown to interact with paxillin (Turner et al., 1990) and specifically to 
paxillin’s LD2 domain (Brown et al., 1996) by performing an FP assay the ACT appears 
to bind the LD2 motif with as well with the same weak binding curved observed for the 
VT (figure 28).While the binding curve can only indicate an inconclusive result, having 
very similar curves, both VT and the ACT sharing similar structure and the knowledge 
that the VT interacts with the LD2 domain raises the possibility that the ACT can interact 
with the LD2 domain.  
Paxillin has been shown to bind both vinculin and talin (Zacharchenko et al., 2016) and 
is implicated in the recruitment of both to FACs (Pasapera et al., 2010). Paxillin 
alongside kindlin and FAK are thought to localise to the cell membrane and form pre-
adhesion complexes and subsequently recruit talin and vinculin which then go on to 
form mature FACs (Atherton et al., 2020).  
The interaction between the ACT and paxillin LD2 could indicate that α-catulin like 
vinculin may be recruited to FACs and once there it may regulate several signalling 
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pathways such as remodelling actin networks through its interaction with the Lbc Rho 
Guanine Nucleotide Exchange Factor (Park et al., 2002). This α-catulin: paxillin 
interaction also could suggest that paxillin may be recruited and present in the DAPC. 
4.3.2 The ACT appears not to interact with VD1 
The structural similarity between the α-catulin and vinculin suggested the possibility that 
α-catulin might undergo head to tail autoinhibitory interactions much like vinculin does 
(Khan and Goult, 2019). The ACH was not able to be expressed but its similarity in with 
VD1 meant that perhaps the ACT could interact with VD1, as such the ACT-VD1 
interaction was solely investigated. Using GF, the ACT was shown not to interact with 
VD1 however the assay was only preliminary, and issues with varying protein 
concentrations mean that the result itself is still inconclusive. 
A Phyre2 (Kelley et al., 2016) generated model of the ACT overlaid over the VT in the 
VD1-VT structure (PDB 1RKE,(Izard et al., 2004) does show similarities in the binding 
interface however although with reduced hydrogen bonds present between the ACT and 
VD1 in comparison to the VT. Also, in the ACT the α4 helix appears to be a disordered 
loop at the region that is in contact with the VD1, in the VT this is a fully structured α- 
helix and has some hydrophobic and polar bonds with VD1. These differences may 
indicate why the ACT does not associate with VD1 however, this is purely based of 
Phyre2 models in PyMOL, and would require repeating the GF and perhaps performing 
other binding assays such a using microscale thermophoresis (MST) to prove if any 




Figure 39-(Top) Overlay of the ACT (green) with VT (red) in an autoinhibited conformational with VD1 
(blue). (Bottom) The α4 helix in the VT has a α-helical structure which enables it to interact with VD1 
through polar and hydrophobic bonds. The ACT lacks α-helical structure in this region and could 
possibly result in less stable interactions between this region and VD1. PDB 1RKE, Izard et al., 2004. 
 
Figure 39-(Top) Overlay of the ACT(red) with VT(green) in an autoinhibited conformational with 
VD1(blue).(Bottom) The α4 helix in the VT has a α-helical structure which enables it to interact with VD 
through polar and hydrophobic bonds. The ACT lacks α-helical structure in this region and could 






4.2.3 Is it possible for the ACH bind to talin VBS in the same way as VD1? 
The ACH’s homology to VD1 suggested that the ACH could indeed bind to talin VBS in 
the same helical bundle method as VD1, however with the ACH not expressing and 
attempts to clone the ACH into more suitable vectors were unsuccessful this prediction 
was not able to be tested.  
However by using Phyre2 a model of the ACH can be overlaid with the WT VD1-Helix4 
(PDB1SYQ,(Izard and Vonrhein, 2004) structure to give some idea as if the ACH could 
indeed bind talin VBS (figure 39A). Overlaying the two structures conserved residues in 
VD1 are seen in the ACH, P15 which in VD1 allows the α1 helix to incorporate VBS is 
present at the same point in the ACH P42 as well as the semi conserved VD1 Q19 
which hydrogen bonds with serine in many VBS and also is seen in the ACH Q46 
(figure 39B).  
Many of the hydrophobic residues found in the core of the VD1 interaction with VBSs 
are also seen in the ACH, one residue difference in the ACH however may inhibit a talin 
VBS binding to the ACH. In VD1 L54 is positioned between two hydrophobic residues in 
the VBS peptide and contributes to the VBS tight binding, in the ACH the leucine is 
replaced by F81, while phenylalanine is hydrophobic its large aromatic ring may disrupt 
the VBS peptide from properly aligning with the other hydrophobic residues that line the 
VD1 hydrophobic core (figure 39C). While the position of F81 could disrupt binding the 
homology of ACH to VD1 still suggests the possibility of the ACH binding to a talin VBS 




α-catulin could bind to a talin though a ACH-VBS interaction after being transported to  
FACs through its interaction with paxillin’s LD2 motif in a very similar manner to vinculin, 
α-catulin’s further signalling roles could help regulate and remodel FACs much as it 
does in the DAPC. 
 
Figure 40-A) Overlay of the ACH (green) with WT VD1-H4 (blue, yellow) with interface residues side 
chains are modelled using the interfaceresidues.py script in PyMOL. B) Both P15 and Q19 are 
conserved in the ACH as P42 and Q46, the proline enables the curve seen in the α1 helix of VD1 and 
the glutamine enables a conserved hydrogen bond between serine. C) The hydrophobic core of VD1 
and ACH are similar in hydrophobic residue placement and amino acid, apart from in the ACH the large 
F81 residue replaces L54 in VD1. F81 could interfere with talin VBS helixes bind to the ACH. PDB 
1SYQ, Izard and Vonrhein, 2004. 
 
 
Figure 40-A) Overlay of the ACH (green) with WT VD1 (blue)-H4 (yellow) with interface residues side 
chains are modelled using the interfaceresidues.py script in PyMOL. B) Both P15 and Q19 are 
conserved in the ACH as P42 and Q46, the proline enables the curve seen in the α1 helix of VD1 and 
the glutamine enables a conserved hydrogen bond between serine. C) The hydrophobic core of VD1 
and ACH are similar in hydrophobic residue placement and amino acid, apart from in the ACH the large 
F81 residue replaces L54 in VD1. F81 could interfere with talin VBS helixes bind to the ACH. PDB 


































5 Future work  
5.1 Project 1:C.caviae TarP VBS study  
The ability of TarP VBS3 to bind to VD1 and TarP VBS1-3 being shown to interact with 
VD1 in a 1:3 ratio has opened the idea that all three TarP VBS can bind tightly to VD1 at 
once and each TarP VBS may have specific roles in pathogenesis. To aid in 
corroborating the 1:3 ratio of VD1 binding to C.caviae TarP VBS1-3, the affinity of the 
C.caviae TarP VBS2 for VD1 will need to be quantified by FP much like TarP VBS1 and 
3. C.caviae TarP also contains two actin binding regions either side of TarP VBS3, 
comparisons in actin’s ability to bind to TarP in the presence of VD1 could prove if the 
binding of actin and VD1 are mutually exclusive or perhaps exist in varying 
stoichiometries of VD1 binding. A crystal structure of both the TarP VBS2 with VD1 
would complete the trio of TarP VBS and allow analysis and comparison between the 
three TarP VBS. Also, a crystal structure of TarP VBS1-3 with VD1 could also aid in 
clarifying if the stoichiometry of 1:3 TarP VBS1-3  to VD1 binding is correct. Lastly the 
difference in affinity between TarP VBS1 and three was proposed to because of a pair 
of threonines in TarP VBS1 replacing a valine and leucine. By mutating the pair of 
threonines to a valine and leucine and then performing an FP assay could confirm if it is 
indeed these threonines causing the difference in affinity. 
5.2 Project 2:VD1 lethality rescuing mutant study 
While the W253X-H50 structure was obtained and some unique binding interactions are 
seen the W253X mutant itself does not interfere with the talin VBS binding, and while 
the W253X has shown to rescue lethality in Drosophila with hyperactive vinculin the 
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W253X-H50 does not reveal clear mechanism of how. A proteomic approach may help 
to identify if any additional interactions are seen with the W253X mutant, that may 
identify how it rescues the lethality phenotype. To acquire crystal structures of the A50I 
and P15L mutants as well as possibly some double mutants such P15LW253X in a 
complex with H50 would allow a better understanding of why H50 seems more able to 
incorporate VD1 mutations when binding. 
5.3 Project 3:α-catulin-vinculin homology study 
To better understand whether α-catulin shares binding interactions with many of the 
same proteins as vinculin, constructs such like the ACH could be cloned into a more 
suitable expression vector and binding assays such as FP, MST, NMR and crystal 
structures could be performed with talin VBSs to ascertain if the ACH can interact with 
talin in the same helical bundle method as VD1.  
The interaction between the ACT and VD1 was inconclusive and would need repeating 
with proper controls and additionally if the ACH was able to be expressed GF/SEC-
MALS assays could be performed to examine the interaction between the ACH and 
ACT, which could possibly mimic the VD1-VT autoinhibited structure seen in vinculin. 
Both the VT and α-catenin tail have been shown to bind and bundle actin, an actin co-
sedimentation assay could be performed identify whether the ACT also binds and 
bundles actin.  
α-catenin has been shown to contain a VBS which can bind to VD1 (Rangarajan and 
Izard, 2012; Yao et al., 2014b), this VBS is not conserved in vinculin, however it 
appears to be conserved in α-catulin (figure 40). By performing an FP assay with a α-
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catulin VBS peptide with VD1 a possible interaction could be identified (Note a peptide 
of the α-catulin VBS was designed and ordered but production was unsuccessful).  
BAD AVG GOOD 
α-catulinVBS|335-369   AYTSHEHRERILELSSQARTELQQLLSVWMQTQSR 
α-cateninVBS|323-357   SCTRDDRRERIVAECNAVRQALQDLLSEYMGNAGR 
cons                   : * .::****:  .. .*  **:*** :* . .* 
Additionally, a GF/SEC-MALS assay could be performed  with the α-catulin VBS present 
in a larger ‘α-catulin VBS’ construct and run with VD1 could identify an interaction (Note 
attempts to clone the ‘α-catulin VBS’ from the α-catulin full length were attempted but 
unsuccessful). Additionally the α-catenin VBS is present in a force dependant domain 
that exposes the VBS only when force is applied across the domain (Yao et al., 2014b), 
α-catulin appears to share homology in this region and single molecule force stretching 
experiments could indicate if α-catulin’s proposed VBS is also positioned in a force 
dependant domain.  
Lastly α-catulin residues 1-377 has been shown to interact with α-dystrobrevin 1 
residues 468-590 (Oh et al., 2012) and further analysis of the α-dystrobrevin 1 residues 
468-590 reveals what could be a VBS, which could in theory then interact with the 
ACH.A MSA reveals some conservation between this α-dystrobrevin 1 VBS and talin 
helix 58 VBS (figure 41). If able to express the ACH a FP assay could be performed 
with a peptide of the α-dystrobrevin 1 VBS.(Note like the α-catulin VBS mentioned in 
above a peptide of the α-dystrobrevin 1 VBS was designed and ordered failed to be 
synthesised). 
Figure 41-MSA of the α-catulin VBS and the α-catenin VBS indicating high conservation of residues 
between the two, indicating that α-catulin may possibly be able to bind Vinculin as α-catenin has 
been shown to. Alignment made using T-Coffee alignment server. 
 
Figure 41-Multiple sequence alignment of the α-catulin VBS and the α-catenin VBS indicating high 
conservation of residues between the two, indicating that α-catulin may possibly be able to bind 
Vinculin as α-catenin has been shown to. Alignment made using T-Coffee alignment server. 
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BAD AVG GOOD 
α-Dystrobrevin_1_VBS |620-645     DLLVAADSITNTMSSLVKELNSEVAS 
Talin_1_H58_VBS      |2345-2369   -ILEAAKSIAAATSALVKAASAAQRE 
 
cons                               :* **.**: : *:***  .:   . 
6 Final conclusions  
Throughout this study new data has been collected that help to answer some questions 
on the role of vinculin in the chlamydial pathogenesis cycle, also to visualise the W253X 
lethality mutant and its unique interaction with talin helix 50 VBS and lastly identify and 
explore some structural similarities between vinculin and one of its homologs α-catulin. 
Many of the experiments carried out in this study were in progress when the COVID-19 
pandemic arose and the labs were closed, as such attempts to repeat some less 
complete results were hindered unfortunately.  
6.1 Project 1 C.caviae TarP VBS study 
The data shown in chapter one suggests that C.caviae TarP VBS3 does bind VD1 and 
with a higher affinity than TarP VBS1, and the TarP VBS3-VD1 crystal identifies residue 
differences that may indicate why the affinities for TarP VBS1 and 3 are different. The 
GST pulldown data also suggests that all three of C.caviae TarP VBS can be bound to 
VD1 at once. This data suggests that all three of C.caviae TarP VBSs can bind to VD1, 
but with TarP VBS1 and VBS3 showing different affinities this could indicate that each 
VBS is required only at certain steps in the chlamydial pathogenesis cycle. 
Figure 42-MSA of the proposed α-Dystrobrevin-1-VBS and the talin VBS helix 58 indicating good 
conservation of residues which may indicate that the ACH interacts with the α-Dystrobrevin-1’s C-
terminal through a VBS interaction much like is seen between talin VBS and VD1. Alignment made 
using T-Coffee alignment server. 
 
Figure 42-Multiple sequence alignment of the proposed α-Dystrobrevin-1-VBS and the talin VBS helix 
58 indicating good conservation of residues which may indicate that the ACH interacts with the α-
Dystrobrevin-1’s C-terminal through a VBS interaction much like is seen between talin VBS and VD1. 
Alignment made using T-Coffee alignment server. 
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6.2 Project 2 VD1 lethality rescuing mutant study 
The W253X-H50 crystal structure identified some small but key differences from the 
lack of the last 6 residues in VD1, such as the α1 helix movement towards the H50 VBS 
as well as a change of orientation of a key K2099 residue when compared to the WT 
VD1-H50 structure. Sequence and structural comparison of the H50 VBS with other 
talin VBSs identified that smaller side chain residues, alongside K2099’s potential to 
interact with the α1 helix may allow flexibility in H50 VBS binding to the VD1 lethality 
rescuing mutants such as A50I and P15L.  
6.3 Project 3 α-catulin-vinculin homology study 
The similarities between vinculin and α-catulin were seen in some Far UV CD 
secondary structure analysis confirming α-helical structure of the ACT. It was also 
shown that the ACT potentially interacts with paxillin’s LD2 domain like the VT and 
opens the possibility that the α-catulin like vinculin could be recruited to FACs through 
an interaction with paxillin. Sequence analysis as well as models of the ACH overlaid on 
VD1 revealed the possibility that the ACH could bind talin VBS in the same helical 
bundle method as VD1. This indicates the potential for α-catulin binding to talin in FACs 
and potentially regulating actin networks, as well asking the question of whether all the 
talin VBS are specific to vinculin or perhaps could the two structurally homologous 
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